Details of Disease

Disease Name

Endometrial carcinoma

endometrial cancer; endometrium carcinoma; endometrial carcinoma (disease); endometrial carcinoma; carcinoma, endometrial, malignant; carcinoma of the endometrium; carcinoma of endometrium

Definition

A malignant tumor arising from the epithelium that lines the cavity of the uterine body. The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases. Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma. Uterine bleeding is an initial clinical sign. The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.

Disease Hierarchy

DISH9F1N: Carcinoma

DISJC5KW: Uterine carcinoma

DISW0LMR: Endometrial cancer

DISXR5CY: Endometrial carcinoma

Disease Identifiers

MONDO ID

MONDO_0002447

MESH ID

D016889

UMLS CUI

C0476089

OMIM ID

608089

MedGen ID

96903

HPO ID

HP:0012114

SNOMED CT ID

254878006

General Information of Disease (ID: DISXR5CY)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Arsenic trioxide	DM61TA4	Approved	Small molecular drug	[1]
Megesterol acetate	DMQ1Q37	Approved	NA	[2]
Progesterone	DMUY35B	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 303 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCC9	TTEF5MJ	Limited	Biomarker	[4]
ADH7	TT3LE7P	Limited	Altered Expression	[5]
AGR2	TT9K86S	Limited	Altered Expression	[6]
AGTR1	TT8DBY3	Limited	Biomarker	[7]
AKT2	TTH24WI	Limited	Biomarker	[8]
AMHR2	TTZDCPK	Limited	Altered Expression	[9]
AR	TTKPW01	Limited	Biomarker	[10]
ATAD2	TT9A0HI	Limited	Biomarker	[11]
BGN	TT0JPVF	Limited	Biomarker	[12]
BRD2	TTDP48B	Limited	Biomarker	[13]
BRS3	TTKYEPM	Limited	Altered Expression	[14]
CALCR	TTLWS2O	Limited	Biomarker	[15]
CCNE1	TTCEJ4F	Limited	Altered Expression	[16]
CD24	TTCTYNP	Limited	Biomarker	[17]
CDC25C	TTESBNC	Limited	Biomarker	[18]
CDK1	TTH6V3D	Limited	Altered Expression	[19]
CEACAM1	TTA9CK4	Limited	Altered Expression	[20]
CGA	TTFC29G	Limited	Altered Expression	[21]
CGB3	TTUH273	Limited	Altered Expression	[21]
COASY	TT4YO0Z	Limited	Altered Expression	[22]
CSE1L	TTTRULD	Limited	Biomarker	[23]
CSF1	TT0IQER	Limited	Biomarker	[24]
DFFA	TTYVQ9C	Limited	Altered Expression	[25]
DFFB	TT2SRE0	Limited	Altered Expression	[25]
DHCR24	TTTK0NH	Limited	Biomarker	[26]
EIF4EBP1	TTKGEBL	Limited	Biomarker	[27]
ENG	TTB30LE	Limited	Altered Expression	[28]
ESRRG	TT9ZRHB	Limited	Biomarker	[29]
EZR	TTE47YC	Limited	Altered Expression	[30]
FASN	TT7AOUD	Limited	Altered Expression	[31]
FLT4	TTDCBX5	Limited	Biomarker	[32]
FOXO1	TTLRVIA	Limited	Biomarker	[33]
GNA11	TTSRXJW	Limited	Biomarker	[22]
GNRH1	TT0ID4A	Limited	Genetic Variation	[34]
GPI	TT19JIZ	Limited	Altered Expression	[35]
HDGF	TTKGV26	Limited	Altered Expression	[36]
HNF1A	TT01M3K	Limited	Biomarker	[33]
HOXA11	TTEX4ZA	Limited	Biomarker	[37]
HTRA1	TT8POQR	Limited	Biomarker	[38]
IFNB1	TT4TZ8J	Limited	Biomarker	[39]
IGFBP7	TTUQ01B	Limited	Biomarker	[40]
ITGA4	TTJMF9P	Limited	Biomarker	[41]
JAK1	TT6DM01	Limited	Altered Expression	[24]
KCNN4	TT7M9I6	Limited	Altered Expression	[42]
KDM4A	TTZHPB8	Limited	Biomarker	[43]
KITLG	TTDJ51N	Limited	Biomarker	[44]
LPA	TTU9LGY	Limited	Biomarker	[45]
LPAR1	TTQ6S1K	Limited	Biomarker	[45]
MAP3K4	TT1RSX7	Limited	Biomarker	[4]
MDM2	TT9TE0O	Limited	Biomarker	[46]
MMP11	TTZW4MV	Limited	Biomarker	[47]
MMP7	TTMTWOS	Limited	Genetic Variation	[48]
MTA1	TTO4HUS	Limited	Altered Expression	[27]
MTDH	TTH6SA5	Limited	Biomarker	[49]
MUC16	TTC1PS3	Limited	Biomarker	[50]
NME1	TTDY8JH	Limited	Genetic Variation	[51]
NR0B2	TT25A9Q	Limited	Biomarker	[52]
OGG1	TTRU01G	Limited	Genetic Variation	[53]
PAK4	TT7Y3BZ	Limited	Biomarker	[54]
PDCD1	TTNBFWK	Limited	Altered Expression	[55]
PIK3CB	TT9H4P3	Limited	Biomarker	[56]
PPIA	TTL2ADK	Limited	Biomarker	[57]
PPME1	TTXQ54R	Limited	Biomarker	[58]
PROM1	TTXMZ81	Limited	Altered Expression	[59]
PSMD10	TT2H4LN	Limited	Biomarker	[60]
PTGES2	TTWU04I	Limited	Biomarker	[61]
PTPN6	TT369M5	Limited	Biomarker	[52]
RAD51	TTC0G1L	Limited	Genetic Variation	[62]
RUNX3	TTKCVO7	Limited	Altered Expression	[63]
RXFP1	TTMAHD1	Limited	Altered Expression	[64]
S100A6	TT716MY	Limited	Biomarker	[65]
SCGB1A1	TTONPVW	Limited	Altered Expression	[66]
SERPINA6	TTJL8VG	Limited	Altered Expression	[67]
SKP2	TT5B2EO	Limited	Altered Expression	[68]
SLC22A16	TTITAVR	Limited	Biomarker	[69]
SLC2A4	TTP6MT5	Limited	Altered Expression	[70]
SLC6A8	TTYUHB5	Limited	Biomarker	[15]
SNCG	TT5TQNZ	Limited	Altered Expression	[71]
SOCS3	TTI0ME6	Limited	Biomarker	[37]
STC1	TTDLUER	Limited	Biomarker	[72]
XPA	TTGT87E	Limited	Genetic Variation	[73]
ALCAM	TT2AFT6	Disputed	Biomarker	[74]
CCNA2	TTAMQ62	Disputed	Biomarker	[75]
EGLN1	TT9ISBX	Disputed	Biomarker	[76]
FOLR1	TTVC37M	Disputed	Genetic Variation	[77]
HGFAC	TTD96RW	Disputed	Altered Expression	[78]
NEDD4	TT1QU6G	Disputed	Altered Expression	[79]
SATB1	TTLFRIC	Disputed	Biomarker	[80]
SLC7A5	TTPH2JB	Disputed	Altered Expression	[81]
ST14	TTPRO7W	Disputed	Altered Expression	[78]
VEGFD	TTOM5H4	Disputed	Altered Expression	[32]
ABCC1	TTOI92F	moderate	Biomarker	[82]
ATXN2	TTPQJ7P	moderate	Genetic Variation	[83]
BCL11A	TTR61MW	moderate	Genetic Variation	[83]
BIRC5	TTTPU1G	moderate	Biomarker	[84]
CDK8	TTBJR4L	moderate	Altered Expression	[85]
CLDN4	TTMTS9H	moderate	Altered Expression	[86]
DCN	TTB3XAN	moderate	Altered Expression	[87]
EIF2AK4	TT9U4EP	moderate	Genetic Variation	[83]
ETS1	TTTGPSD	moderate	Altered Expression	[88]
FGF7	TTFY134	moderate	Altered Expression	[89]
FGR	TTPOGS1	moderate	Biomarker	[90]
FOLR2	TTT54CI	moderate	Biomarker	[91]
KLK4	TT4319X	moderate	Altered Expression	[92]
LEPR	TT0HD6V	moderate	Altered Expression	[93]
LTF	TTSZDQU	moderate	Biomarker	[94]
PDE7A	TT1BC3A	moderate	Biomarker	[95]
RNF43	TTD91BL	moderate	Genetic Variation	[96]
SETD2	TTPC3H4	moderate	Biomarker	[97]
SH2B3	TT36N7Z	moderate	Genetic Variation	[83]
SRD5A2	TTT02K8	moderate	Altered Expression	[45]
ACKR3	TTRQJTC	Strong	Altered Expression	[98]
ADAMTS1	TTS2TEI	Strong	Altered Expression	[99]
ADIPOQ	TTXKA7D	Strong	Genetic Variation	[100]
AGPAT2	TT9AYVR	Strong	Biomarker	[101]
AKR1B1	TTFBNVI	Strong	Biomarker	[102]
AKR1C3	TT5ZWB6	Strong	Altered Expression	[103]
ANGPT2	TTKLQTJ	Strong	Biomarker	[104]
ANO1	TTOJI4S	Strong	Biomarker	[105]
ARRB1	TTMVD4A	Strong	Biomarker	[106]
ARRB2	TT8SO2I	Strong	Altered Expression	[107]
ASRGL1	TT4WT91	Strong	Biomarker	[108]
ATR	TT8ZYBQ	Strong	Biomarker	[109]
BMI1	TTIPNSR	Strong	Biomarker	[110]
BRCA2	TTUARD6	Strong	Genetic Variation	[111]
BRD3	TTHE657	Strong	Biomarker	[13]
BRD7	TT07ZS1	Strong	Biomarker	[112]
BST2	TT90BJT	Strong	Biomarker	[113]
BTG1	TTL7N2W	Strong	Altered Expression	[114]
C1QBP	TTWTD7F	Strong	Altered Expression	[115]
CACNA2D3	TTN7T29	Strong	Biomarker	[116]
CASP5	TTWR48J	Strong	Genetic Variation	[117]
CASP7	TTM7Y45	Strong	Genetic Variation	[118]
CCK	TT90CMU	Strong	Biomarker	[119]
CCNB1	TT9P6OW	Strong	Biomarker	[120]
CCND1	TTFCJ7S	Strong	Altered Expression	[121]
CCND3	TT1JXNR	Strong	Altered Expression	[122]
CD55	TT5Z9WY	Strong	Altered Expression	[123]
CD9	TTZEIBV	Strong	Altered Expression	[82]
CDC20	TTBKFDV	Strong	Biomarker	[124]
CDC25A	TTLZS4Q	Strong	Biomarker	[125]
CDK7	TTQYF7G	Strong	Altered Expression	[126]
CDKN1C	TTBSUAR	Strong	Biomarker	[127]
CHEK2	TT9ABMF	Strong	Genetic Variation	[128]
CHST15	TTFK7E1	Strong	Genetic Variation	[129]
CLDN6	TTKSV48	Strong	Altered Expression	[130]
COMT	TTKWFB8	Strong	Genetic Variation	[131]
CRHR2	TTIY658	Strong	Biomarker	[132]
CRY1	TT5MLZR	Strong	Biomarker	[133]
CSPG4	TT7MYXI	Strong	Altered Expression	[134]
CTSV	TTSD9T1	Strong	Biomarker	[135]
CUL3	TTPCU0Q	Strong	Genetic Variation	[136]
CXCL11	TTWG0RE	Strong	Biomarker	[137]
CYP11A1	TTSYVO6	Strong	Biomarker	[138]
CYP3A4	TTWP7HQ	Strong	Genetic Variation	[139]
DDC	TTN451K	Strong	Genetic Variation	[140]
DDX5	TTZKPVC	Strong	Biomarker	[36]
DEPTOR	TTLYP6D	Strong	Biomarker	[141]
DGKA	TTGL8F0	Strong	Biomarker	[142]
DNMT3B	TT6VZ78	Strong	Altered Expression	[143]
EGFL7	TT7WD0H	Strong	Biomarker	[144]
EIF2AK2	TTXEZJ4	Strong	Altered Expression	[15]
EP300	TTGH73N	Strong	Biomarker	[145]
EPCAM	TTZ8WH4	Strong	Biomarker	[146]
EPHB1	TT8MDAC	Strong	Biomarker	[147]
EPHB2	TTKPV6O	Strong	Biomarker	[148]
EPHB4	TTI4ZX2	Strong	Biomarker	[149]
ERAP1	TT60XFL	Strong	Biomarker	[150]
ESRRA	TTPNQAC	Strong	Biomarker	[151]
ESRRB	TTKF0XS	Strong	Biomarker	[152]
EZH2	TT9MZCQ	Strong	Biomarker	[153]
F2RL2	TTVSEBF	Strong	Altered Expression	[154]
F2RL3	TTD0652	Strong	Biomarker	[155]
FAM83B	TT1Q347	Strong	Biomarker	[156]
FBXW7	TT29KY7	Strong	Altered Expression	[157]
FECH	TTQ6VF4	Strong	Biomarker	[158]
FGF1	TTMY81X	Strong	Biomarker	[159]
FGF10	TTNPEFX	Strong	Biomarker	[160]
FGF18	TT6ICRA	Strong	Altered Expression	[161]
FGF4	TTCEKVZ	Strong	Altered Expression	[162]
FGF8	TTIUF3J	Strong	Biomarker	[161]
FOSL2	TT689IR	Strong	Biomarker	[163]
FOXC2	TTLBAP1	Strong	Biomarker	[164]
FTO	TTFW3BT	Strong	Biomarker	[165]
GALR1	TTX3HNZ	Strong	Genetic Variation	[166]
GNRHR	TT8R70G	Strong	Biomarker	[167]
GPC3	TTJTSX4	Strong	Altered Expression	[168]
HAAO	TTWON83	Strong	Posttranslational Modification	[169]
HOXB13	TTZ6I58	Strong	Altered Expression	[170]
HPN	TT25MVL	Strong	Altered Expression	[171]
HSD17B13	TTDJYZR	Strong	Altered Expression	[172]
HSD17B4	TTL1WGS	Strong	Genetic Variation	[173]
HSPA5	TTW26OG	Strong	Biomarker	[174]
HTR1B	TTK8CXU	Strong	Biomarker	[175]
IFNAR1	TTSYFMA	Strong	Biomarker	[176]
IGF1R	TTQFBMY	Strong	Biomarker	[177]
IGFBP6	TTLAYV8	Strong	Altered Expression	[178]
IL11RA	TTZPLJS	Strong	Biomarker	[179]
IRAK1	TTXAJWN	Strong	Biomarker	[180]
KDM1A	TTNR0UQ	Strong	Altered Expression	[181]
KISS1	TTU2O6T	Strong	Altered Expression	[182]
KISS1R	TT3KBZY	Strong	Altered Expression	[182]
KLK1	TT5T3P6	Strong	Altered Expression	[183]
KLK5	TTULSEW	Strong	Altered Expression	[184]
KLK8	TTH5MRS	Strong	Biomarker	[185]
KRT17	TTKV0EC	Strong	Biomarker	[186]
LAPTM4B	TTEJQT0	Strong	Genetic Variation	[187]
LASP1	TTZJA87	Strong	Biomarker	[188]
LCN2	TTKTLAI	Strong	Biomarker	[189]
LHCGR	TT2O4W9	Strong	Genetic Variation	[190]
LILRB2	TTHC6XU	Strong	Biomarker	[191]
LNPEP	TTY2KP7	Strong	Biomarker	[192]
LPAR2	TTB7Y8I	Strong	Biomarker	[45]
LRP6	TTSXOWE	Strong	Altered Expression	[59]
MAOB	TTGP7BY	Strong	Biomarker	[193]
MAP2K7	TT6QY3J	Strong	Biomarker	[194]
MAP3K1	TTW8TJI	Strong	Genetic Variation	[195]
MAPK11	TT73U6C	Strong	Biomarker	[196]
MGLL	TTZ963I	Strong	Altered Expression	[197]
MGMT	TTJ8DV7	Strong	Biomarker	[198]
MMP14	TTJ4QE7	Strong	Altered Expression	[199]
MSI1	TTSM4BA	Strong	Biomarker	[200]
MSLN	TT4RXME	Strong	Biomarker	[146]
MSMB	TTYH1ZK	Strong	Biomarker	[201]
MSR1	TT2TDH9	Strong	Altered Expression	[202]
MSTN	TTM8I2X	Strong	Altered Expression	[203]
MTNR1B	TT32JK8	Strong	Biomarker	[204]
MUTYH	TTNB0ZK	Strong	Genetic Variation	[205]
MYC	TTNQ5ZP	Strong	Biomarker	[206]
NCOA3	TT124R0	Strong	Biomarker	[207]
NELL1	TT7H4BF	Strong	Altered Expression	[208]
NFE2L2	TTA6ZN2	Strong	Altered Expression	[209]
NPY5R	TTY6EWA	Strong	Altered Expression	[210]
NR1H3	TTECBXN	Strong	Biomarker	[121]
NR4A1	TTMXE2Q	Strong	Biomarker	[211]
NRP2	TTRXUVC	Strong	Altered Expression	[208]
NTSR1	TTTUMEP	Strong	Posttranslational Modification	[212]
OLFM4	TTK1CX7	Strong	Altered Expression	[213]
P2RY2	TTOZHQC	Strong	Biomarker	[214]
PAK1	TTFN95D	Strong	Altered Expression	[215]
PAWR	TT3I4WV	Strong	Altered Expression	[155]
PBK	TTMY6BZ	Strong	Biomarker	[216]
PCSK6	TT75LN9	Strong	Altered Expression	[217]
PDGFD	TTSN0GA	Strong	Altered Expression	[218]
PGC	TT7K6AD	Strong	Altered Expression	[219]
PIM2	TT69J2Z	Strong	Biomarker	[220]
PKN1	TTSL41O	Strong	Biomarker	[221]
PLOD2	TT8MEUD	Strong	Biomarker	[222]
PMS1	TTX1ISF	Strong	Genetic Variation	[223]
PRDX5	TTLPJWH	Strong	Biomarker	[224]
PRLR	TTBPXMA	Strong	Biomarker	[225]
PRMT1	TTVOJAI	Strong	Biomarker	[145]
PSMB8	TTEAD9J	Strong	Altered Expression	[226]
PTPN7	TT2C1DT	Strong	Biomarker	[227]
RICTOR	TT143WL	Strong	Altered Expression	[228]
ROR1	TTDEJAU	Strong	Biomarker	[229]
ROR2	TTUDPCI	Strong	Biomarker	[229]
RPS6KA6	TT3KYWB	Strong	Posttranslational Modification	[230]
RPSA	TTLUW5B	Strong	Altered Expression	[231]
RRM2	TT1S4LJ	Strong	Biomarker	[232]
RXFP3	TT64ZVP	Strong	Altered Expression	[169]
S100A4	TTPR5SX	Strong	Altered Expression	[233]
SCUBE2	TTWREQP	Strong	Biomarker	[234]
SGO1	TTBPKGD	Strong	Biomarker	[235]
SGPL1	TT618Q2	Strong	Biomarker	[236]
SIRPA	TTBRJS9	Strong	Biomarker	[237]
SIRT5	TTH0IOD	Strong	Altered Expression	[238]
SLC1A5	TTF7WRM	Strong	Altered Expression	[239]
SLC38A1	TT1YE9Z	Strong	Biomarker	[239]
SLC9A1	TTGSEFH	Strong	Altered Expression	[240]
SRC	TT6PKBN	Strong	Biomarker	[241]
SREBF1	TTER0UB	Strong	Altered Expression	[242]
SSRP1	TTETDKQ	Strong	Biomarker	[243]
STC2	TT4EFTR	Strong	Biomarker	[244]
STEAP1	TT9E64S	Strong	Altered Expression	[245]
TACR3	TTBPGLU	Strong	Biomarker	[246]
TERF2	TT5XSLT	Strong	Biomarker	[247]
TGFB3	TTWOMY8	Strong	Biomarker	[248]
TMPRSS6	TTL9KE7	Strong	Biomarker	[204]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[249]
TNFSF10	TTA5MS9	Strong	Biomarker	[236]
TNFSF12	TTBTDM1	Strong	Altered Expression	[250]
TNK2	TTIET93	Strong	Genetic Variation	[251]
TNKS2	TTFQI4H	Strong	Genetic Variation	[247]
TOP2B	TT4NVEM	Strong	Genetic Variation	[252]
TPX2	TT0PHL4	Strong	Biomarker	[253]
TRIM27	TTTO3QN	Strong	Altered Expression	[254]
TWIST1	TTX1MY7	Strong	Altered Expression	[255]
UTS2R	TTW5UDX	Strong	Genetic Variation	[256]
VEGFA	TT3LJ9K	Strong	Altered Expression	[257]
VSIR	TT51SK8	Strong	Altered Expression	[258]
VTCN1	TTCK85E	Strong	Biomarker	[259]
ZFP36L1	TT8QVJO	Strong	Altered Expression	[260]
ABCC4	TTUEAFL	Definitive	Biomarker	[261]
CEACAM3	TTPX7I5	Definitive	Biomarker	[262]
CTCFL	TTY0RZT	Definitive	Altered Expression	[263]
GLO1	TTV9A7R	Definitive	Altered Expression	[264]
KRT19	TT3JF9E	Definitive	Altered Expression	[265]
NR1H2	TTXA6PH	Definitive	Biomarker	[121]
PCNA	TTLG1PD	Definitive	Altered Expression	[266]
PTP4A3	TT7YM8D	Definitive	Biomarker	[267]
QPCT	TTJ7YTV	Definitive	Genetic Variation	[268]
VEGFB	TTPJQHE	Definitive	Biomarker	[223]
------------------------------------------------------------------------------------


⏷ Show the Full List of 303 DTT(s)

This Disease Is Related to 6 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC14A2	DT8QC7K	Strong	Genetic Variation	[256]
SLC27A1	DTKDTML	Strong	Altered Expression	[269]
SLC27A6	DTG4CWJ	Strong	Altered Expression	[269]
SLC2A3	DT9SQ3L	Strong	Altered Expression	[269]
SLC2A6	DTS4MKQ	Strong	Altered Expression	[270]
SLC39A10	DTK02RZ	Strong	Genetic Variation	[271]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DTP(s)

This Disease Is Related to 18 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
HSD17B7	DEDMWFX	Limited	Altered Expression	[172]
ACSS2	DEE76VW	Disputed	Biomarker	[272]
HSD3B1	DERDQWN	Disputed	Altered Expression	[138]
HSD3B2	DEN0GVQ	Disputed	Altered Expression	[138]
AKR1C1	DE7P2FB	moderate	Biomarker	[273]
AKR1B10	DEP6GT1	Strong	Altered Expression	[274]
BAAT	DERA3OF	Strong	Genetic Variation	[275]
CHST3	DEQIZP2	Strong	Biomarker	[276]
CYP3A7	DERD86B	Strong	Altered Expression	[277]
GGCT	DEKW6PB	Strong	Altered Expression	[278]
HPGD	DEHKSC6	Strong	Altered Expression	[279]
MT2A	DEFKGT7	Strong	Biomarker	[204]
PER1	DE9HF0I	Strong	Genetic Variation	[133]
PGPEP1	DEVDR46	Strong	Biomarker	[280]
SULT2A1	DE0P6LK	Strong	Biomarker	[277]
SULT2B1	DEZBN53	Strong	Biomarker	[281]
UGT2B17	DEAZDL8	Strong	Altered Expression	[282]
UGT2B7	DEB3CV1	Strong	Altered Expression	[277]
------------------------------------------------------------------------------------


⏷ Show the Full List of 18 DME(s)

This Disease Is Related to 461 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADIPOR1	OT65ZFZN	Limited	Biomarker	[283]
ARMC3	OTF6M9MM	Limited	Altered Expression	[284]
AXIN2	OTRMGQNU	Limited	Biomarker	[117]
AZIN2	OT8OB7CG	Limited	Biomarker	[285]
CD82	OTH8MC64	Limited	Altered Expression	[286]
CDH13	OTD2CYM5	Limited	Genetic Variation	[287]
CDX2	OTCG4TSY	Limited	Biomarker	[288]
CIB1	OT4BVCRU	Limited	Biomarker	[44]
CKS1B	OTNUPLUJ	Limited	Biomarker	[44]
COX2	OTTMVBJJ	Limited	Altered Expression	[289]
CSMD2	OT541Z3W	Limited	Genetic Variation	[83]
CTBP2	OTGZGT87	Limited	Biomarker	[201]
CTCF	OT8ZB70U	Limited	Biomarker	[290]
CTHRC1	OTV88X2G	Limited	Biomarker	[291]
ELAVL2	OT6EJ8MQ	Limited	Biomarker	[292]
ERCC2	OT1C8HQ4	Limited	Genetic Variation	[293]
ERVW-1	OTWV8DXJ	Limited	Altered Expression	[294]
FCHSD2	OTKXLIJ6	Limited	Genetic Variation	[83]
GADL1	OTJM4A0R	Limited	Biomarker	[285]
GNA14	OTYZ1ZI0	Limited	Biomarker	[22]
GPR42	OTEB0ROY	Limited	Altered Expression	[14]
H2AX	OT18UX57	Limited	Biomarker	[295]
HOXA10	OTB6GQ09	Limited	Altered Expression	[296]
HSD17B6	OTSB55D2	Limited	Altered Expression	[5]
HTRA2	OTC7616F	Limited	Biomarker	[297]
KLF9	OTBFEJRQ	Limited	Altered Expression	[298]
LEF1	OTWS5I5H	Limited	Altered Expression	[299]
LGR6	OTPZ1PWR	Limited	Altered Expression	[300]
LSR	OTR8Y32X	Limited	Biomarker	[301]
MBD2	OTUQPP0R	Limited	Biomarker	[302]
MRE11	OTGU8TZM	Limited	Genetic Variation	[303]
MSH3	OTD3YPVL	Limited	Biomarker	[304]
MYBL2	OTZ3JX8Q	Limited	Biomarker	[11]
NAV3	OT97M1TR	Limited	Genetic Variation	[83]
NCOA1	OTLIUJQD	Limited	Biomarker	[305]
NEU1	OTH9BY8Y	Limited	Biomarker	[144]
NEURL1	OT2C4P70	Limited	Biomarker	[144]
NUCB2	OTHO6JWN	Limited	Biomarker	[306]
OR9Q1	OTLDBPE6	Limited	Genetic Variation	[307]
PDCD4	OTZ6NXUX	Limited	Altered Expression	[308]
PDIK1L	OTISF4KG	Limited	Biomarker	[309]
PGK1	OT6V1ICH	Limited	Altered Expression	[310]
PLPPR4	OTBOWTC5	Limited	Genetic Variation	[83]
PPP1R14C	OTZ3F6D2	Limited	Genetic Variation	[83]
PRDM2	OT8L7CGX	Limited	Biomarker	[311]
PROK1	OT8S7RUG	Limited	Biomarker	[312]
RAD50	OTYMU9G1	Limited	Genetic Variation	[303]
RPL10	OTBHOZGC	Limited	Genetic Variation	[313]
RPL11	OT3VZ6OE	Limited	Genetic Variation	[313]
SKAP1	OTD4ZKAL	Limited	Genetic Variation	[307]
SLN	OTERIU75	Limited	Biomarker	[314]
SMUG1	OT2YIOCQ	Limited	Biomarker	[315]
SOCS2	OTBPNKJQ	Limited	Altered Expression	[87]
SRSF10	OTY6IJ11	Limited	Biomarker	[316]
SUMO1	OTJFD4P5	Limited	Altered Expression	[317]
TBC1D9	OTSSCTB5	Limited	Altered Expression	[318]
TET1	OTZDHT1D	Limited	Altered Expression	[264]
TFAP2C	OTUDIW05	Limited	Altered Expression	[319]
TGFBR3	OTQOOUC4	Limited	Genetic Variation	[320]
THEMIS2	OTI1OBLN	Limited	Biomarker	[321]
TSPYL2	OTGGW2EF	Limited	Biomarker	[4]
TTF1	OT4K90WD	Limited	Biomarker	[322]
ACCS	OTHIHI9D	Disputed	Biomarker	[272]
AQP2	OTQLBKK6	Disputed	Altered Expression	[323]
C19orf33	OTOYH74A	Disputed	Altered Expression	[324]
CCN3	OTOW5YL4	Disputed	Biomarker	[325]
HAND2	OTCXYW4Y	Disputed	Biomarker	[326]
LPXN	OTUNV3CK	Disputed	Altered Expression	[327]
NBN	OT73B5MD	Disputed	Genetic Variation	[303]
PLA2G15	OT6VJTPA	Disputed	Biomarker	[272]
PRDX3	OTLB2WEU	Disputed	Biomarker	[224]
SIRT7	OT5M4OT4	Disputed	Biomarker	[328]
APOD	OTT77XW8	moderate	Altered Expression	[329]
ARID1B	OTILK3Q7	moderate	Altered Expression	[330]
BPTF	OTD1RZAD	moderate	Genetic Variation	[83]
CABLES1	OTMN4XSX	moderate	Altered Expression	[331]
CCDC54	OTW5WCX9	moderate	Altered Expression	[263]
CNBP	OTTGM9NK	moderate	Biomarker	[332]
COX7A2L	OTY21FKV	moderate	Biomarker	[333]
CPVL	OTOJL31C	moderate	Genetic Variation	[83]
EEFSEC	OTJ4KKOO	moderate	Genetic Variation	[83]
EMP2	OTPS2H0L	moderate	Biomarker	[334]
EVI2A	OTR8RUXQ	moderate	Genetic Variation	[83]
EXT1	OTRPALJK	moderate	Genetic Variation	[83]
FOXA1	OTEBY0TD	moderate	Biomarker	[335]
HNF1B	OTSYIC3T	moderate	Genetic Variation	[83]
INHA	OT7HWCO3	moderate	Altered Expression	[336]
KLLN	OTV3FPH0	moderate	Genetic Variation	[337]
NCAM2	OT8LBJN8	moderate	Genetic Variation	[83]
PIK3R2	OTZSUQK5	moderate	Biomarker	[338]
PTPRD	OTZPJ3GX	moderate	Biomarker	[307]
RAB32	OTTR4H7S	moderate	Posttranslational Modification	[339]
RAP1GAP	OTC31ONQ	moderate	Biomarker	[340]
SCAF1	OT16TM3N	moderate	Altered Expression	[333]
SCGB2A1	OT9L87U9	moderate	Biomarker	[341]
SCRIB	OTW4N3FV	moderate	Altered Expression	[342]
SEMA3F	OTQFMS8S	moderate	Altered Expression	[343]
SIX1	OT70YYWM	moderate	Altered Expression	[344]
SLC12A9	OTR7VRAK	moderate	Biomarker	[200]
SMARCB1	OT2LP7LJ	moderate	Biomarker	[345]
SPA17	OT8J7T7U	moderate	Altered Expression	[263]
SSPN	OTYG2SL7	moderate	Genetic Variation	[83]
TSNAX	OTZ9SGWB	moderate	Biomarker	[346]
AATF	OT1QOKLD	Strong	Biomarker	[347]
ABCF2	OTXIBZ3N	Strong	Altered Expression	[348]
ABHD5	OTY829Z3	Strong	Biomarker	[349]
ACP1	OTJ9CKLU	Strong	Genetic Variation	[350]
ADARB1	OTGKSZEV	Strong	Posttranslational Modification	[351]
ADD2	OTRCPCD2	Strong	Biomarker	[352]
ADGRG2	OTPAD5S1	Strong	Altered Expression	[353]
ADSL	OTSNJALL	Strong	Biomarker	[354]
AFDN	OTTRU341	Strong	Altered Expression	[355]
AMELX	OTIN26MM	Strong	Altered Expression	[356]
AMH	OT5FH4BD	Strong	Biomarker	[357]
ANO2	OT650E98	Strong	Biomarker	[358]
ANXA3	OTDD8OI7	Strong	Biomarker	[359]
APBB3	OTNUTR0N	Strong	Altered Expression	[202]
ARHGEF1	OTXU4HBW	Strong	Biomarker	[360]
ARHGEF7	OT9BPJCL	Strong	Altered Expression	[361]
ARTN	OTWIWGL6	Strong	Altered Expression	[362]
ASCC1	OTH4VAP9	Strong	Altered Expression	[361]
ASCL2	OT3D62WB	Strong	Biomarker	[175]
ASS1	OT4ZMG0Q	Strong	Biomarker	[141]
ATAD1	OTJ02XFL	Strong	Genetic Variation	[363]
ATP6AP2	OT0IABVV	Strong	Altered Expression	[364]
AXIN1	OTRGZGZ5	Strong	Genetic Variation	[365]
BARD1	OTTC0Z9Y	Strong	Genetic Variation	[366]
BBS2	OTPF9JIB	Strong	Altered Expression	[367]
BCL10	OT47MCLI	Strong	Biomarker	[368]
BCOR	OTG013AX	Strong	Genetic Variation	[369]
BHLHE22	OTZUQY5L	Strong	Biomarker	[326]
BHLHE40	OTITX14U	Strong	Biomarker	[370]
BHLHE41	OTY9GJ1Y	Strong	Biomarker	[370]
BLM	OTEJOAJX	Strong	Genetic Variation	[371]
BRCA1	OT5BN6VH	Strong	Biomarker	[372]
C1GALT1C1	OTRTZUF5	Strong	Genetic Variation	[373]
CALB1	OTM7IXDG	Strong	Altered Expression	[374]
CAMK4	OT47RDGV	Strong	Biomarker	[375]
CAMKMT	OTLJBRUW	Strong	Biomarker	[376]
CAPG	OTJ86KI6	Strong	Biomarker	[23]
CASZ1	OTWJ2OR8	Strong	Biomarker	[377]
CAVIN3	OTOLBK79	Strong	Genetic Variation	[378]
CCDC6	OTXRQDYG	Strong	Genetic Variation	[379]
CCDC7	OTNCL9JR	Strong	Biomarker	[380]
CCNG1	OT17IA9L	Strong	Altered Expression	[381]
CDC42SE2	OT8SG9I1	Strong	Biomarker	[382]
CDC73	OT6JASZ1	Strong	Biomarker	[383]
CDO1	OTLG1P77	Strong	Posttranslational Modification	[326]
CELF4	OT4FS4F5	Strong	Biomarker	[384]
CGRRF1	OTLMNRCL	Strong	Altered Expression	[385]
CHD4	OTBDEHDP	Strong	Genetic Variation	[386]
CHFR	OTRAD2TT	Strong	Biomarker	[387]
CHL1	OT6E6E8P	Strong	Biomarker	[388]
CIDEA	OTDUTSOV	Strong	Posttranslational Modification	[169]
CIRBP	OTXWTPBL	Strong	Biomarker	[389]
CLDN3	OT71MN9S	Strong	Biomarker	[390]
CLDN7	OTNE0XHQ	Strong	Biomarker	[391]
COL11A2	OT3BQUBH	Strong	Biomarker	[332]
COL14A1	OTLNJ13O	Strong	Biomarker	[392]
COPZ2	OTM5W0BK	Strong	Posttranslational Modification	[393]
CPEB1	OTLCXC6H	Strong	Altered Expression	[394]
CREG1	OTRHJ8HK	Strong	Biomarker	[271]
CRKL	OTOYSD1R	Strong	Altered Expression	[395]
CTBP1	OTVYH2DH	Strong	Biomarker	[396]
CTNNBIP1	OTX9SBJG	Strong	Biomarker	[397]
DAB1	OTPL9MA3	Strong	Altered Expression	[398]
DAB2	OTRMQTMZ	Strong	Biomarker	[399]
DAB2IP	OTF456VC	Strong	Genetic Variation	[400]
DACH1	OTMKNAGG	Strong	Biomarker	[401]
DCC	OT2C1SHW	Strong	Altered Expression	[402]
DCTN6	OTI8PIN9	Strong	Biomarker	[403]
DDT	OTF5HTYL	Strong	Biomarker	[404]
DDX39B	OTEVCFVU	Strong	Biomarker	[174]
DDX3X	OTDO4TRX	Strong	Altered Expression	[405]
DDX53	OTHK3EGZ	Strong	Biomarker	[406]
DENND1A	OTONDAA0	Strong	Genetic Variation	[190]
DHRS11	OTU3J0ZL	Strong	Altered Expression	[172]
DLGAP4	OTNELLIN	Strong	Genetic Variation	[407]
DOLPP1	OTRHICBA	Strong	Biomarker	[408]
DPH7	OTTD7ZZ8	Strong	Genetic Variation	[267]
DPYSL4	OT3SBS2S	Strong	Biomarker	[392]
DROSHA	OTCE68KZ	Strong	Altered Expression	[409]
DUSP6	OT4H6RKW	Strong	Altered Expression	[410]
DYNLL2	OTLIT58K	Strong	Genetic Variation	[411]
E2F6	OT2PN28R	Strong	Biomarker	[412]
E2F7	OTWW358N	Strong	Biomarker	[412]
EBAG9	OTTQLQCP	Strong	Altered Expression	[413]
EDIL3	OTDVVNS0	Strong	Altered Expression	[414]
EFNA2	OTEAUKRX	Strong	Biomarker	[415]
EIF3C	OTR8RF9X	Strong	Altered Expression	[416]
EIF3H	OT61RBF5	Strong	Altered Expression	[416]
EIF4G1	OT2CF1E6	Strong	Altered Expression	[416]
EIF5	OT79PQUN	Strong	Biomarker	[416]
EIF6	OTEXMUED	Strong	Biomarker	[416]
ELF1	OTV5LKIA	Strong	Biomarker	[415]
ELF5	OTLRU8YF	Strong	Altered Expression	[417]
ELOF1	OT8BXS5U	Strong	Biomarker	[415]
EMP3	OTODMJ1D	Strong	Biomarker	[358]
ENOSF1	OT65D3ZK	Strong	Genetic Variation	[418]
ERCC4	OTFIOPG1	Strong	Biomarker	[223]
ERMP1	OT9CIEO2	Strong	Altered Expression	[419]
ERRFI1	OT7VZ2IZ	Strong	Biomarker	[420]
ERV3-1	OT4CW64T	Strong	Biomarker	[421]
ERVV-2	OTDFQ5AR	Strong	Altered Expression	[421]
ETF1	OTH8C5U5	Strong	Altered Expression	[260]
ETV5	OTE2OBM4	Strong	Biomarker	[422]
FAM98A	OTBLMZXO	Strong	Altered Expression	[423]
FANCD2	OTVEB5LF	Strong	Biomarker	[424]
FAT4	OT7QONNV	Strong	Altered Expression	[425]
FEN1	OT6QGG7O	Strong	Genetic Variation	[426]
FGF17	OTAQSFZ2	Strong	Biomarker	[161]
FGF3	OT9PK2SI	Strong	Genetic Variation	[427]
FHDC1	OTMMV8ZN	Strong	Biomarker	[144]
FLOT1	OT0JPPJZ	Strong	Altered Expression	[428]
FOXA2	OTJOCVOY	Strong	Biomarker	[429]
FOXD3	OTXYV6GO	Strong	Biomarker	[430]
FZD6	OTBCPII8	Strong	Altered Expression	[59]
GAB2	OTBFN705	Strong	Altered Expression	[431]
GALNT6	OTOQQVH1	Strong	Biomarker	[432]
GEMIN2	OT4L6TLL	Strong	Altered Expression	[433]
GHRH	OT94U6MO	Strong	Biomarker	[434]
GINS3	OT8NVXTD	Strong	Altered Expression	[435]
GKN1	OT7ZYFQ9	Strong	Biomarker	[436]
GNRH2	OTORRM53	Strong	Biomarker	[167]
GOLPH3	OTDLGYM3	Strong	Biomarker	[437]
GORASP2	OTL3PLD2	Strong	Biomarker	[438]
GOT2	OT6XBWN0	Strong	Altered Expression	[269]
GPCPD1	OTFE3RCV	Strong	Altered Expression	[439]
GPR68	OT1NXSMN	Strong	Altered Expression	[440]
GPRC5A	OTPOCWR7	Strong	Biomarker	[441]
GREB1	OTU6ZA26	Strong	Altered Expression	[442]
GZMA	OT43R33L	Strong	Altered Expression	[443]
H4C1	OTB71W46	Strong	Biomarker	[444]
HERPUD1	OT9EROL6	Strong	Biomarker	[445]
HIVEP1	OT7CAG4A	Strong	Biomarker	[446]
HJURP	OTWMV16B	Strong	Biomarker	[84]
HOMER2	OT4JGKJF	Strong	Altered Expression	[447]
HOXB3	OT9UC5PE	Strong	Altered Expression	[448]
HOXB9	OTMVHQOU	Strong	Biomarker	[449]
HOXD13	OTWSC8TF	Strong	Biomarker	[148]
HPR	OTXSC9UB	Strong	Genetic Variation	[450]
HS3ST2	OTWFA0GJ	Strong	Biomarker	[451]
HYAL1	OT2SJN0X	Strong	Altered Expression	[452]
HYAL2	OTTVINXW	Strong	Altered Expression	[452]
HYAL3	OTG6VUSP	Strong	Biomarker	[452]
IFI27	OTI2XGIT	Strong	Biomarker	[403]
IGSF9	OTNTKWS2	Strong	Biomarker	[453]
IL27RA	OTSQBAKI	Strong	Biomarker	[454]
ING5	OTRNNSFM	Strong	Altered Expression	[455]
INHBB	OT2QLD11	Strong	Altered Expression	[456]
INTS2	OT2N5TCK	Strong	Genetic Variation	[427]
IPO13	OT887N3O	Strong	Biomarker	[457]
IPO8	OTBHGNKT	Strong	Altered Expression	[458]
IQGAP1	OTZRWTGA	Strong	Altered Expression	[459]
JAZF1	OTXTYSYD	Strong	Biomarker	[201]
JPH4	OTRLNPJK	Strong	Altered Expression	[460]
JPT1	OT6CRZEU	Strong	Biomarker	[461]
JUNB	OTG2JXV5	Strong	Altered Expression	[462]
KCNE1	OTZNQUW9	Strong	Biomarker	[463]
KDM4B	OT5P1UPY	Strong	Altered Expression	[43]
KIF15	OTJRJEXL	Strong	Biomarker	[253]
KIF5B	OTT34MT8	Strong	Altered Expression	[56]
KIFC1	OTNQDS00	Strong	Biomarker	[253]
KLF12	OTVH4KD4	Strong	Altered Expression	[464]
KLRC3	OT9EPHV3	Strong	Biomarker	[354]
KMT2C	OTC59BCO	Strong	Genetic Variation	[369]
KNSTRN	OTYA7UXS	Strong	Biomarker	[292]
KRT5	OTVGI9HT	Strong	Altered Expression	[465]
LAMC1	OTIG527N	Strong	Altered Expression	[466]
LAT	OTZC1XZ1	Strong	Biomarker	[467]
LEFTY2	OT3RX4QF	Strong	Altered Expression	[468]
LGALS7	OTMSVI7R	Strong	Altered Expression	[469]
LLGL1	OTAIQSXZ	Strong	Altered Expression	[470]
LRG1	OTLD0KWA	Strong	Biomarker	[471]
LRPPRC	OTXSK5LP	Strong	Biomarker	[454]
LYL1	OTCNOV1M	Strong	Biomarker	[472]
LYPD5	OTGP7UKA	Strong	Biomarker	[27]
MACC1	OTV3DLX0	Strong	Altered Expression	[473]
MACROD1	OTWFEVRW	Strong	Altered Expression	[474]
MAGI2	OTXDDKZS	Strong	Biomarker	[475]
MAL	OTBM30SW	Strong	Biomarker	[476]
MAML3	OTZFV53Z	Strong	Altered Expression	[477]
MAP2K4	OTZPZX11	Strong	Altered Expression	[478]
MARCHF3	OT89V4N5	Strong	Altered Expression	[479]
MARCHF7	OTG9SF10	Strong	Altered Expression	[480]
MARCHF8	OTH7PNN2	Strong	Genetic Variation	[481]
MARCKSL1	OT13J2FM	Strong	Biomarker	[482]
MAX	OTKZ0YKM	Strong	Biomarker	[483]
MBD4	OTWR9YXE	Strong	Genetic Variation	[117]
MDC1	OTEUQH4J	Strong	Biomarker	[303]
MDH2	OT7364GY	Strong	Altered Expression	[484]
MECOM	OTP983W8	Strong	Altered Expression	[485]
MED15	OT0D0JVD	Strong	Biomarker	[441]
METTL14	OT6TPQMH	Strong	Genetic Variation	[486]
MINDY4	OTBZ2SZB	Strong	Biomarker	[487]
MLH3	OT91PPBI	Strong	Genetic Variation	[488]
MMP26	OT9O89KU	Strong	Altered Expression	[489]
MRPL19	OTRBKF6R	Strong	Altered Expression	[458]
MRPS18B	OT1K9PFX	Strong	Altered Expression	[490]
MSN	OTZJ4J6G	Strong	Biomarker	[491]
MT1E	OTXJKU4Y	Strong	Altered Expression	[492]
MUC6	OTPVL723	Strong	Altered Expression	[493]
MZF1	OTMVZCPW	Strong	Altered Expression	[494]
NAPSA	OT6F8IAL	Strong	Biomarker	[495]
NCOA2	OTMQFPBB	Strong	Biomarker	[496]
NDUFAB1	OTF906UR	Strong	Genetic Variation	[350]
NECTIN2	OTIE0W6O	Strong	Altered Expression	[497]
NEDD4L	OT1B19RU	Strong	Altered Expression	[498]
NELL2	OTS4MJZ7	Strong	Altered Expression	[208]
NFYA	OTWFFOVH	Strong	Biomarker	[499]
NID1	OTKLBLS6	Strong	Biomarker	[422]
NKX2-1	OTCMEJTA	Strong	Altered Expression	[500]
NLRP7	OTE9BI32	Strong	Biomarker	[501]
NMU	OTW9X7BQ	Strong	Biomarker	[502]
NOL3	OT1K0L0D	Strong	Biomarker	[253]
NR2F1	OTGWZWYL	Strong	Biomarker	[503]
NRIP1	OTIZOJQV	Strong	Biomarker	[504]
NSD2	OTQ6SW4R	Strong	Biomarker	[505]
NTMT1	OTLRH78U	Strong	Genetic Variation	[506]
NUDT9	OTUYF0H3	Strong	Biomarker	[507]
NUP98	OTNT12G2	Strong	Posttranslational Modification	[351]
NUPR1	OT4FU8C0	Strong	Biomarker	[422]
OTUB1	OT8WWM9O	Strong	Altered Expression	[508]
PAEP	OTQA0NV4	Strong	Altered Expression	[509]
PAQR5	OTGGWXQE	Strong	Altered Expression	[510]
PAQR7	OTIWX5AM	Strong	Altered Expression	[510]
PAQR8	OTGZ8W9F	Strong	Altered Expression	[510]
PARD3	OTH5BPLO	Strong	Altered Expression	[154]
PAX1	OT0Y3MIM	Strong	Biomarker	[511]
PAX2	OTKP1N8F	Strong	Biomarker	[512]
PAX8	OTRPD9MI	Strong	Biomarker	[513]
PCBP4	OTDLL4NB	Strong	Altered Expression	[514]
PCDH10	OT2GIT0E	Strong	Biomarker	[515]
PDIA3	OTHPQ0Q3	Strong	Altered Expression	[516]
PELP1	OTVXQNOT	Strong	Altered Expression	[517]
PIK3R1	OT5BZ1J9	Strong	Genetic Variation	[518]
PIWIL1	OT7CRGZ3	Strong	Biomarker	[519]
PIWIL2	OT1PXQIF	Strong	Biomarker	[520]
PLEK	OTB73XXA	Strong	Genetic Variation	[521]
PLXNA1	OTN0BING	Strong	Altered Expression	[522]
PLXNA3	OTMZIBVG	Strong	Biomarker	[522]
PMS2	OTNLWTMI	Strong	Biomarker	[523]
PNN	OT0HXICH	Strong	Biomarker	[524]
POLD1	OTWO4UCJ	Strong	Genetic Variation	[525]
POT1	OTNBXJCQ	Strong	Biomarker	[526]
POU4F3	OTILD0XS	Strong	Biomarker	[475]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[527]
PRAP1	OT48QD82	Strong	Genetic Variation	[528]
PRB1	OTV0SYMD	Strong	Altered Expression	[529]
PRB2	OTAD4JZ0	Strong	Altered Expression	[530]
PRG2	OT0BCPQG	Strong	Biomarker	[446]
PSMD4	OTH1VZTM	Strong	Altered Expression	[531]
PSMD9	OT6Y5CC3	Strong	Biomarker	[403]
PSME3	OTSTC4YY	Strong	Genetic Variation	[532]
PTPN18	OT0S09B3	Strong	Biomarker	[533]
PTPRA	OTZA82J1	Strong	Altered Expression	[534]
RARRES1	OTETUPP5	Strong	Biomarker	[441]
RASSF1	OTEZIPB7	Strong	Posttranslational Modification	[535]
RB1	OT9VMY7B	Strong	Altered Expression	[536]
RBL1	OTDEBFYC	Strong	Altered Expression	[529]
RBL2	OTBQSOE6	Strong	Altered Expression	[537]
RBMX	OTFZN66E	Strong	Biomarker	[297]
REEP5	OTZU4TJI	Strong	Genetic Variation	[538]
RELB	OTU3QYEF	Strong	Genetic Variation	[539]
RHOC	OTOLE1FT	Strong	Altered Expression	[540]
RIT1	OTVNOGOH	Strong	Altered Expression	[541]
RLN2	OTY3OG71	Strong	Altered Expression	[64]
RNASE1	OTKZ7CO9	Strong	Genetic Variation	[542]
RNF144B	OTN7FCDE	Strong	Biomarker	[543]
RPL17	OTTYMPS6	Strong	Biomarker	[544]
RPL22	OTVCN8K0	Strong	Genetic Variation	[545]
RPL36A	OT1LYV85	Strong	Biomarker	[420]
RRBP1	OT4ZTPTM	Strong	Biomarker	[546]
SALL4	OTC08PR5	Strong	Biomarker	[547]
SATB2	OT2W80XC	Strong	Biomarker	[548]
SCAF11	OTX59D0X	Strong	Altered Expression	[433]
SEMA3B	OTCZCPMS	Strong	Altered Expression	[549]
SEMA5A	OTUOIOJV	Strong	Altered Expression	[550]
SERPINF2	OTZGAF8B	Strong	Biomarker	[551]
SESN1	OTSFDZWL	Strong	Biomarker	[552]
SFN	OTLJCZ1U	Strong	Altered Expression	[553]
SHBG	OTPWU5IW	Strong	Genetic Variation	[554]
SIRT4	OT5S0J23	Strong	Altered Expression	[238]
SKP1	OT5BPAZ4	Strong	Biomarker	[555]
SLIT3	OTU8MKEU	Strong	Biomarker	[556]
SMAD2	OTC6VB4K	Strong	Biomarker	[557]
SMARCA2	OTSGJ8SV	Strong	Genetic Variation	[558]
SMARCE1	OTAX4ITH	Strong	Biomarker	[559]
SMOC2	OTK1EQ49	Strong	Altered Expression	[59]
SOCS4	OTIRULFZ	Strong	Biomarker	[560]
SOCS5	OTN1ABYR	Strong	Altered Expression	[560]
SOCS6	OT2O5ZBK	Strong	Biomarker	[560]
SOX1	OTVI1RAR	Strong	Biomarker	[561]
SOX17	OT9H4WWE	Strong	Altered Expression	[562]
SOX18	OTPUMHWA	Strong	Biomarker	[563]
SOX3	OT1CRCOB	Strong	Biomarker	[564]
SOX4	OTSS40SS	Strong	Altered Expression	[563]
SOX6	OTT0W0LE	Strong	Biomarker	[565]
SOX7	OTOZOFAG	Strong	Altered Expression	[299]
SPAM1	OTMPOB4E	Strong	Biomarker	[452]
SPATA2	OTOA45GL	Strong	Biomarker	[544]
SPINT1	OT1CLR5L	Strong	Biomarker	[433]
SPINT2	OTQV7BKQ	Strong	Biomarker	[433]
SPOCK2	OTXSVTSA	Strong	Biomarker	[199]
SPON1	OTC06MY4	Strong	Biomarker	[566]
SPOP	OTP0107S	Strong	Genetic Variation	[567]
SPP2	OTX254AR	Strong	Genetic Variation	[568]
ST6GALNAC1	OT3JQD99	Strong	Genetic Variation	[373]
STARD13	OTB4U1HY	Strong	Genetic Variation	[411]
STIP1	OT7TXLOX	Strong	Genetic Variation	[569]
SUFU	OT0IRYG1	Strong	Altered Expression	[570]
SUSD2	OTSJTAZP	Strong	Altered Expression	[571]
SUZ12	OT655XF8	Strong	Biomarker	[201]
TBX5	OT70PISV	Strong	Biomarker	[326]
TCEAL7	OTNPDZCN	Strong	Altered Expression	[572]
TCF4	OTB9ASTK	Strong	Biomarker	[573]
TCHP	OTVDMHSY	Strong	Biomarker	[574]
TEAD1	OTK6971C	Strong	Altered Expression	[301]
TEAD4	OTJS0T2B	Strong	Altered Expression	[575]
TES	OTL8PP6V	Strong	Posttranslational Modification	[576]
TET3	OT76U3YF	Strong	Biomarker	[577]
TFAP2B	OTR1T8E9	Strong	Biomarker	[578]
TFF3	OTJJDRTU	Strong	Altered Expression	[579]
THADA	OTYZQX0F	Strong	Genetic Variation	[190]
THBS2	OTXET551	Strong	Altered Expression	[580]
THUMPD1	OTKU8KWH	Strong	Biomarker	[581]
TICAM2	OTK7GIJ5	Strong	Biomarker	[403]
TIMM8A	OTDX9687	Strong	Genetic Variation	[126]
TIPRL	OTS2FZ8O	Strong	Posttranslational Modification	[582]
TMED7	OTONO8E6	Strong	Biomarker	[403]
TMEFF2	OT1WZ2QO	Strong	Altered Expression	[583]
TNFAIP8	OT1G9297	Strong	Genetic Variation	[584]
TNXB	OTVBWAV5	Strong	Biomarker	[585]
TOPBP1	OT6UPZPD	Strong	Genetic Variation	[252]
TOX4	OTSOXQFN	Strong	Biomarker	[586]
TRA2B	OTZYQW52	Strong	Biomarker	[587]
TRAF4	OTJLRVMC	Strong	Altered Expression	[588]
TRAM1	OT3I0H8E	Strong	Biomarker	[589]
TRIM22	OTJBLG5R	Strong	Biomarker	[590]
TRIM44	OT0B1T2B	Strong	Biomarker	[591]
TSHZ1	OTYQ9ECW	Strong	Genetic Variation	[592]
TSPYL5	OT7QEI2X	Strong	Biomarker	[593]
CBLL2	OTB4AD3V	Definitive	Genetic Variation	[136]
CCL18	OT7JYSK9	Definitive	Altered Expression	[56]
CEACAM7	OTKFDTZY	Definitive	Biomarker	[262]
EFEMP2	OT0I2B4J	Definitive	Biomarker	[446]
ELF3	OTUTLEQO	Definitive	Biomarker	[594]
HMMR	OT4M0JTZ	Definitive	Altered Expression	[595]
HTRA3	OTXJ0H4X	Definitive	Biomarker	[596]
MAPK8IP2	OTDUHLN0	Definitive	Biomarker	[597]
MUC20	OTYYE1GK	Definitive	Biomarker	[598]
MUL1	OT2JC9YR	Definitive	Genetic Variation	[136]
NOP53	OTA2YKO6	Definitive	Altered Expression	[599]
POLE	OTFM3MMU	Definitive	Genetic Variation	[600]
PTPRN	OTAP7NOL	Definitive	Biomarker	[597]
RBM10	OTES2MES	Definitive	Altered Expression	[257]
RBP1	OTRP1MFC	Definitive	Biomarker	[601]
RETN	OTW5Z1NH	Definitive	Genetic Variation	[602]
SMARCA1	OT0Y6PTU	Definitive	Altered Expression	[330]
SRA1	OTYOGMTG	Definitive	Biomarker	[241]
TRIB3	OTG5OS7X	Definitive	Altered Expression	[463]
------------------------------------------------------------------------------------


⏷ Show the Full List of 461 DOT(s)

References

1	Arsenic trioxide FDA Label
2	Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis. Exp Biol Med (Maywood). 2021 Nov;246(21):2307-2316.
3	Progesterone FDA Label
4	Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.Nat Genet. 2012 Dec;44(12):1310-5. doi: 10.1038/ng.2455. Epub 2012 Oct 28.
5	Expression of a retinol dehydrogenase (hRoDH-4), a member of the retinol/steroid dehydrogenase family implicated in retinoic acid biosynthesis, in normal and neoplastic endometria.Am J Obstet Gynecol. 2002 Apr;186(4):675-83. doi: 10.1067/mob.2002.122127.
6	High AGR2 protein is a feature of low grade endometrial cancer cells.Oncotarget. 2018 Jul 31;9(59):31459-31472. doi: 10.18632/oncotarget.25838. eCollection 2018 Jul 31.
7	Silencing of angiotensin receptor 1 interferes with angiotensin II oncogenic activity in endometrial cancer.J Cell Biochem. 2018 Nov;119(11):9110-9121. doi: 10.1002/jcb.27174. Epub 2018 Aug 13.
8	Genetic alterations in endometrial cancer by targeted next-generation sequencing.Exp Mol Pathol. 2016 Feb;100(1):8-12. doi: 10.1016/j.yexmp.2015.11.026. Epub 2015 Nov 25.
9	Transcriptome analysis reveals that Mllerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesis.Int J Oncol. 2015 May;46(5):2039-46. doi: 10.3892/ijo.2015.2920. Epub 2015 Mar 6.
10	Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11.J Mol Med (Berl). 2019 Sep;97(9):1315-1327. doi: 10.1007/s00109-019-01809-6. Epub 2019 Jun 29.
11	ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.Oncotarget. 2015 Sep 29;6(29):28440-52. doi: 10.18632/oncotarget.4955.
12	Biglycan enhances the ability of migration and invasion in endometrial cancer.Arch Gynecol Obstet. 2016 Feb;293(2):429-38. doi: 10.1007/s00404-015-3844-5. Epub 2015 Aug 15.
13	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14.
14	The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.Int J Gynecol Cancer. 2013 Jan;23(1):52-9. doi: 10.1097/IGC.0b013e31827912b8.
15	Significance of calreticulin as a prognostic factor in endometrial cancer.Oncol Lett. 2018 Jun;15(6):8999-9008. doi: 10.3892/ol.2018.8495. Epub 2018 Apr 13.
16	Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.Oncotarget. 2017 Feb 28;8(9):14794-14805. doi: 10.18632/oncotarget.11605.
17	Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines.Mol Cancer Ther. 2015 Oct;14(10):2353-63. doi: 10.1158/1535-7163.MCT-15-0187. Epub 2015 Jul 30.
18	Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium.Oncology. 2003;65(2):159-66. doi: 10.1159/000072342.
19	Paired box 2 promotes progression of endometrial cancer via regulating cell cycle pathway.J Cancer. 2018 Sep 25;9(20):3743-3754. doi: 10.7150/jca.22418. eCollection 2018.
20	Stimulation of CEACAM1 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187 in endometrial carcinoma cells.Carcinogenesis. 2006 Mar;27(3):483-90. doi: 10.1093/carcin/bgi275. Epub 2005 Dec 6.
21	hLH/hCG-receptor expression correlates with in vitro invasiveness in human primary endometrial cancer.Gynecol Oncol. 2008 Dec;111(3):496-501. doi: 10.1016/j.ygyno.2008.08.018. Epub 2008 Oct 1.
22	GNA14 silencing suppresses the proliferation of endometrial carcinoma cells through inducing apoptosis and G(2)/M cell cycle arrest.Biosci Rep. 2018 Sep 7;38(5):BSR20180574. doi: 10.1042/BSR20180574. Print 2018 Oct 31.
23	Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment.Clin Cancer Res. 2017 Nov 1;23(21):6458-6467. doi: 10.1158/1078-0432.CCR-17-0474. Epub 2017 Aug 8.
24	Colonystimulating factor 1 receptor inhibition blocks macrophage infiltration and endometrial cancer cell proliferation.Mol Med Rep. 2019 Apr;19(4):3139-3147. doi: 10.3892/mmr.2019.9963. Epub 2019 Feb 18.
25	Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression.BMC Cancer. 2018 Apr 13;18(1):418. doi: 10.1186/s12885-018-4333-6.
26	Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer.Acta Radiol. 2018 Aug;59(8):1010-1017. doi: 10.1177/0284185117740932. Epub 2017 Nov 14.
27	Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway.Gynecol Oncol. 2019 Jul;154(1):207-217. doi: 10.1016/j.ygyno.2019.04.005. Epub 2019 Apr 9.
28	Expression Profile of Endoglin in Different Grades of Endometrial Cancer.Curr Pharm Biotechnol. 2018;19(12):990-995. doi: 10.2174/1389201020666181127152605.
29	The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERR through AKT and ERK1/2.Eur J Cancer Prev. 2014 Sep;23(5):418-24. doi: 10.1097/CEJ.0000000000000052.
30	Upregulation of miR-183-5p is responsible for the promotion of apoptosis and inhibition of the epithelial-mesenchymal transition, proliferation, invasion and migration of human endometrial cancer cells by downregulating Ezrin.Int J Mol Med. 2018 Nov;42(5):2469-2480. doi: 10.3892/ijmm.2018.3853. Epub 2018 Sep 4.
31	Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.Oncology. 2013;84(3):166-73. doi: 10.1159/000342967. Epub 2013 Jan 9.
32	Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer.Curr Pharm Biotechnol. 2019;20(12):1004-1010. doi: 10.2174/1389201020666190718164431.
33	Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.Arch Gynecol Obstet. 2018 Nov;298(5):961-969. doi: 10.1007/s00404-018-4893-3. Epub 2018 Sep 11.
34	(99m)Tc-LHRH in tumor receptor imaging.Oncol Lett. 2017 Jul;14(1):569-578. doi: 10.3892/ol.2017.6246. Epub 2017 May 24.
35	Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1.Cell Commun Signal. 2019 Mar 5;17(1):22. doi: 10.1186/s12964-019-0336-4.
36	Hepatoma-Derived Growth Factor and DDX5 Promote Carcinogenesis and Progression of Endometrial Cancer by Activating -Catenin.Front Oncol. 2019 Apr 11;9:211. doi: 10.3389/fonc.2019.00211. eCollection 2019.
37	Transcriptional profiling endometrial carcinomas microdissected from DES-treated mice identifies changes in gene expression associated with estrogenic tumor promotion.Int J Cancer. 2006 Oct 15;119(8):1843-9. doi: 10.1002/ijc.22063.
38	Expression and functional significance of HtrA1 loss in endometrial cancer.Clin Cancer Res. 2011 Feb 1;17(3):427-36. doi: 10.1158/1078-0432.CCR-09-3069. Epub 2010 Nov 23.
39	Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFN-NIS.Hum Gene Ther Clin Dev. 2016 Sep;27(3):111-22. doi: 10.1089/humc.2016.061.
40	IGFBP-rP1 acts as a potential tumor suppressor via the suppression of ERK signaling pathway in endometrial cancer cells.Mol Med Rep. 2017 Aug;16(2):1445-1450. doi: 10.3892/mmr.2017.6713. Epub 2017 Jun 7.
41	Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.Cancer. 2005 Oct 1;104(7):1391-7. doi: 10.1002/cncr.21308.
42	Blockage of intermediate-conductance-Ca(2+) -activated K(+) channels inhibits progression of human endometrial cancer.Oncogene. 2007 Aug 2;26(35):5107-14. doi: 10.1038/sj.onc.1210308. Epub 2007 Feb 19.
43	KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.Oncotarget. 2015 Oct 13;6(31):31702-20. doi: 10.18632/oncotarget.5165.
44	TGF- activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth.Cell Cycle. 2016;15(7):931-47. doi: 10.1080/15384101.2016.1150393.
45	Altered expression of lysophosphatidic acid receptors, in association with the synthesis of estrogens and androgens in type 1 endometrial cancer biology.Gynecol Endocrinol. 2018 May;34(5):422-427. doi: 10.1080/09513590.2017.1409707. Epub 2017 Nov 28.
46	Impact of MDM2, TP53 and P14ARF Polymorphisms on Endometrial Cancer Risk and Onset.In Vivo. 2019 May-Jun;33(3):917-924. doi: 10.21873/invivo.11559.
47	Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer.Oncol Lett. 2018 Jul;16(1):1073-1078. doi: 10.3892/ol.2018.8714. Epub 2018 May 16.
48	Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility.Clin Chem Lab Med. 2010 Mar;48(3):337-44. doi: 10.1515/CCLM.2010.082.
49	MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.Oncotarget. 2016 Jan 26;7(4):4559-69. doi: 10.18632/oncotarget.6610.
50	Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis.Clin Chim Acta. 2019 Jan;488:215-220. doi: 10.1016/j.cca.2018.11.011. Epub 2018 Nov 7.
51	Significant association of genetic polymorphism of human nonmetastatic clone 23 type 1 gene with an increased risk of endometrial cancer.Gynecol Oncol. 2010 Oct;119(1):70-5. doi: 10.1016/j.ygyno.2010.06.013.
52	Immunohistochemical Detection of Hematopoietic Cell-specific Protein-Tyrosine Phosphatase (Tyrosine Phosphatase SHP-1) in a Series of Endometrioid and Serous Endometrial Carcinoma.Appl Immunohistochem Mol Morphol. 2018 Aug;26(7):468-477. doi: 10.1097/PAI.0000000000000456.
53	Association analysis between 8-oxoguanine DNA glycosylase genetic variants and endometrial cancer susceptibility in Chinese Han population.J Pharm Pharmacol. 2015 Apr;67(4):559-64. doi: 10.1111/jphp.12348. Epub 2014 Dec 10.
54	Cross-talk between p21-activated kinase 4 and ER signaling triggers endometrial cancer cell proliferation.Oncotarget. 2017 Jul 12;8(40):68083-68094. doi: 10.18632/oncotarget.19188. eCollection 2017 Sep 15.
55	Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.Gynecol Oncol. 2018 May;149(2):381-387. doi: 10.1016/j.ygyno.2018.02.013. Epub 2018 Mar 21.
56	Macrophage ER promoted invasion of endometrial cancer cell by mTOR/KIF5B-mediated epithelial to mesenchymal transition.Immunol Cell Biol. 2019 Jul;97(6):563-576. doi: 10.1111/imcb.12245. Epub 2019 Mar 14.
57	Down-regulation of focal adhesion signaling in response to cyclophilin A knockdown in human endometrial cancer cells, implicated by cDNA microarray analysis.Gynecol Oncol. 2013 Oct;131(1):191-7. doi: 10.1016/j.ygyno.2013.07.095. Epub 2013 Jul 27.
58	Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models.Tumour Biol. 2016 Sep;37(9):11835-11842. doi: 10.1007/s13277-016-5036-8. Epub 2016 Apr 5.
59	Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma.EBioMedicine. 2019 Feb;40:276-289. doi: 10.1016/j.ebiom.2018.12.044. Epub 2018 Dec 26.
60	Bu Shen Yang Xue Prescription Has Treating Effect on Endometrial Cancer through FSH/PI3K/AKT/Gankyrin/HIF-/cyclinD 1 Pathway in Ishikawa Cells.Evid Based Complement Alternat Med. 2018 Oct 9;2018:8412984. doi: 10.1155/2018/8412984. eCollection 2018.
61	Prostaglandin E2 triggers cytochrome P450 17 hydroxylase overexpression via signal transducer and activator of transcription 3 phosphorylation and promotes invasion in endometrial cancer.Oncol Lett. 2018 Oct;16(4):4577-4585. doi: 10.3892/ol.2018.9165. Epub 2018 Jul 18.
62	Association of polymorphisms in the 5' untranslated region of RAD51 gene with risk of endometrial cancer in the Polish population.Arch Gynecol Obstet. 2014 Nov;290(5):985-91. doi: 10.1007/s00404-014-3305-6. Epub 2014 Jun 15.
63	Loss of RUNX3 is significantly associated with advanced tumor grade and stage in endometrial cancers.Mol Med Rep. 2018 Jun;17(6):8173-8179. doi: 10.3892/mmr.2018.8915. Epub 2018 Apr 23.
64	Relaxin 2/RXFP1 Signaling Induces Cell Invasion via the -Catenin Pathway in Endometrial Cancer.Int J Mol Sci. 2018 Aug 18;19(8):2438. doi: 10.3390/ijms19082438.
65	Isomorph expression of BAG-1 gene, ER and PR in endometrial cancer.Anticancer Res. 2010 Oct;30(10):4103-8.
66	Expression of uteroglobin and matrix metalloproteinase-9 genes in endometrial cancer: relationship to estrogen and progesterone receptor status.Oncol Rep. 2004 Feb;11(2):427-33.
67	Effects of sex steroid hormones on corticosteroid-binding globulin gene expression in human endometrial cancer cell line Ishikawa.Ann Clin Biochem. 1998 Sep;35 ( Pt 5):637-42. doi: 10.1177/000456329803500507.
68	Effects of RNAi-induced Skp2 inhibition on cell cycle, apoptosis and proliferation of endometrial carcinoma cells.Exp Ther Med. 2019 May;17(5):3441-3450. doi: 10.3892/etm.2019.7392. Epub 2019 Mar 13.
69	Expression of organic cation transporter SLC22A16 in human endometria.Int J Gynecol Pathol. 2007 Jan;26(1):53-60. doi: 10.1097/01.pgp.0000225845.67245.b3.
70	Prognostic factors and genes associated with endometrial cancer based on gene expression profiling by bioinformatics analysis.Arch Gynecol Obstet. 2016 Jun;293(6):1287-95. doi: 10.1007/s00404-015-3886-8. Epub 2015 Oct 5.
71	Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform.Oncotarget. 2015 Sep 8;6(26):22553-63. doi: 10.18632/oncotarget.4155.
72	Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro.J Endocrinol. 2008 Jun;197(3):517-29. doi: 10.1677/JOE-08-0043.
73	Nucleotide excision repair genotype and the incidence of endometrial cancer: effect of other risk factors on the association.Gynecol Oncol. 2006 Dec;103(3):891-6. doi: 10.1016/j.ygyno.2006.05.020. Epub 2006 Jun 23.
74	ALCAM shedding at the invasive front of the tumor is a marker of myometrial infiltration and promotes invasion in endometrioid endometrial cancer.Oncotarget. 2018 Mar 30;9(24):16648-16664. doi: 10.18632/oncotarget.24625. eCollection 2018 Mar 30.
75	Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data.Sci Rep. 2019 Jul 9;9(1):9924. doi: 10.1038/s41598-019-46195-8.
76	Downregulation of Proline Hydroxylase 2 and Upregulation of Hypoxia-Inducible Factor 1 are Associated with Endometrial Cancer Aggressiveness.Cancer Manag Res. 2019 Nov 22;11:9907-9912. doi: 10.2147/CMAR.S223421. eCollection 2019.
77	Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.Cancer Med. 2019 Aug;8(10):4678-4687. doi: 10.1002/cam4.2378. Epub 2019 Jul 5.
78	Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells.Oncotarget. 2018 Jan 3;9(16):12682-12694. doi: 10.18632/oncotarget.23913. eCollection 2018 Feb 27.
79	NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling.Gynecol Oncol. 2015 Oct;139(1):127-33. doi: 10.1016/j.ygyno.2015.07.098. Epub 2015 Jul 17.
80	LINC01016 promotes the malignant phenotype of endometrial cancer cells by regulating the miR-302a-3p/miR-3130-3p/NFYA/SATB1 axis.Cell Death Dis. 2018 Feb 21;9(3):303. doi: 10.1038/s41419-018-0291-9.
81	High throughput silencing identifies novel genes in endometrioid endometrial cancer.Taiwan J Obstet Gynecol. 2018 Apr;57(2):217-226. doi: 10.1016/j.tjog.2018.02.009.
82	Loss of motility-related protein 1 (MRP1/CD9) and integrin alpha3 expression in endometrial cancers.Cancer. 2001 Aug 1;92(3):542-8. doi: 10.1002/1097-0142(20010801)92:3<542::aid-cncr1353>3.0.co;2-8.
83	Identification of nine new susceptibility loci for endometrial cancer.Nat Commun. 2018 Aug 9;9(1):3166. doi: 10.1038/s41467-018-05427-7.
84	Identification of key pathways and genes in endometrial cancer using bioinformatics analyses.Oncol Lett. 2019 Jan;17(1):897-906. doi: 10.3892/ol.2018.9667. Epub 2018 Nov 5.
85	Tumor-suppressive effects of CDK8 in endometrial cancer cells.Cell Cycle. 2013 Mar 15;12(6):987-99. doi: 10.4161/cc.24003. Epub 2013 Mar 1.
86	Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas.Histopathology. 2018 Aug;73(2):299-305. doi: 10.1111/his.13525. Epub 2018 May 31.
87	Molecular markers of endometrial carcinoma detected in uterine aspirates.Int J Cancer. 2011 Nov 15;129(10):2435-44. doi: 10.1002/ijc.25901. Epub 2011 Apr 8.
88	Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells.Gynecol Oncol. 2007 Sep;106(3):541-8. doi: 10.1016/j.ygyno.2007.05.024. Epub 2007 Jun 27.
89	Expression of keratinocyte growth factor and its receptor in human endometrial cancer in cooperation with steroid hormones.Int J Oncol. 2008 Mar;32(3):565-74.
90	Use of Porphysomes to detect primary tumour, lymph node metastases, intra-abdominal metastases and as a tool for image-guided lymphadenectomy: proof of concept in endometrial cancer.Theranostics. 2019 Apr 13;9(9):2727-2738. doi: 10.7150/thno.31225. eCollection 2019.
91	Folate receptor- targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study.Oncotarget. 2017 Dec 11;9(1):791-801. doi: 10.18632/oncotarget.23155. eCollection 2018 Jan 2.
92	Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.Int J Gynecol Cancer. 2009 Nov;19(8):1377-83. doi: 10.1111/IGC.0b013e3181a83e1a.
93	Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors.Arch Med Sci. 2017 Feb 1;13(1):228-235. doi: 10.5114/aoms.2017.64721. Epub 2016 Dec 19.
94	Isolation and characterization of a gene encoding human Kruppel-like factor 5 (IKLF): binding to the CAAT/GT box of the mouse lactoferrin gene promoter.Nucleic Acids Res. 1999 Dec 15;27(24):4807-15. doi: 10.1093/nar/27.24.4807.
95	The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.Int J Oncol. 2015 Jul;47(1):325-34. doi: 10.3892/ijo.2015.2986. Epub 2015 May 5.
96	Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.Hum Pathol. 2015 Nov;46(11):1640-6. doi: 10.1016/j.humpath.2015.07.004. Epub 2015 Jul 15.
97	DEC2 expression is positively correlated with HIF-1 activation and the invasiveness of human osteosarcomas.J Exp Clin Cancer Res. 2015 Feb 28;34(1):22. doi: 10.1186/s13046-015-0135-8.
98	The role of the SDF-1/ CXCR7 axis on the growth and invasion ability of endometrial cancer cells.Arch Gynecol Obstet. 2017 Apr;295(4):987-995. doi: 10.1007/s00404-017-4308-x. Epub 2017 Feb 27.
99	PGF2-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer.BMC Cancer. 2010 Sep 14;10:488. doi: 10.1186/1471-2407-10-488.
100	Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis.Obes Res Clin Pract. 2019 Jul-Aug;13(4):329-339. doi: 10.1016/j.orcp.2019.03.006. Epub 2019 Apr 16.
101	Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies.Cancer Res. 2005 Oct 15;65(20):9415-25. doi: 10.1158/0008-5472.CAN-05-0516.
102	Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.Chem Biol Interact. 2013 Feb 25;202(1-3):226-33. doi: 10.1016/j.cbi.2012.11.001. Epub 2012 Nov 9.
103	AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.Mol Cell Endocrinol. 2006 Mar 27;248(1-2):126-35. doi: 10.1016/j.mce.2005.10.009. Epub 2005 Dec 9.
104	Combined silencing of VEGF-A and angiopoietin-2, a more effective way to inhibit the Ishikawa endometrial cancer cell line.Onco Targets Ther. 2019 Feb 14;12:1215-1223. doi: 10.2147/OTT.S194064. eCollection 2019.
105	Identification of candidate target genes for endometrial cancer, such as ANO1, using weighted gene co-expression network analysis.Exp Ther Med. 2019 Jan;17(1):298-306. doi: 10.3892/etm.2018.6965. Epub 2018 Nov 13.
106	Beta-arrestin 2 modulates resveratrol-induced apoptosis and regulation of Akt/GSK3? pathways. Biochim Biophys Acta. 2010 Sep;1800(9):912-8. doi: 10.1016/j.bbagen.2010.04.015. Epub 2010 May 7.
107	-arrestin-2 up-regulates toll-like receptor 2 signaling and inhibits apoptosis in human endometrial cancer heterotransplants in nude mice.BMC Cancer. 2019 Nov 1;19(1):1035. doi: 10.1186/s12885-019-6254-4.
108	Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.Gynecol Oncol. 2018 Apr;149(1):173-180. doi: 10.1016/j.ygyno.2018.02.016. Epub 2018 Mar 2.
109	Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.Cancers (Basel). 2019 Dec 1;11(12):1913. doi: 10.3390/cancers11121913.
110	Silencing Bmi1 expression suppresses cancer stemness and enhances chemosensitivity in endometrial cancer cells.Biomed Pharmacother. 2018 Dec;108:584-589. doi: 10.1016/j.biopha.2018.09.041. Epub 2018 Sep 20.
111	Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.Gynecol Oncol. 2018 Aug;150(2):219-226. doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.
112	The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma.Gynecol Oncol. 2012 Jan;124(1):125-33. doi: 10.1016/j.ygyno.2011.09.026. Epub 2011 Oct 19.
113	Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.Int J Cancer. 2013 Jan 15;132(2):472-84. doi: 10.1002/ijc.27679. Epub 2012 Jul 9.
114	Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes.J Hum Genet. 2001;46(3):155-7. doi: 10.1007/s100380170105.
115	Overexpression of HABP1 correlated with clinicopathological characteristics and unfavorable prognosis in endometrial cancer.Tumour Biol. 2015 Feb;36(2):1299-306. doi: 10.1007/s13277-014-2761-8. Epub 2014 Oct 30.
116	Progesterone induces cell apoptosis via the CACNA2D3/Ca2+/p38 MAPK pathway in endometrial cancer.Oncol Rep. 2020 Jan;43(1):121-132. doi: 10.3892/or.2019.7396. Epub 2019 Oct 31.
117	Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer.Int J Oncol. 2009 Nov;35(5):977-82. doi: 10.3892/ijo_00000411.
118	Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: a population-based, case-control study in a Chinese population.Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2114-22. doi: 10.1158/1055-9965.EPI-09-0152. Epub 2009 Jun 16.
119	The antitumoreffect oflobaplatinagainst Ishikawa endometrial cancer cells in vitroand invivo.Biomed Pharmacother. 2019 Jun;114:108762. doi: 10.1016/j.biopha.2019.108762. Epub 2019 Mar 27.
120	Competing endogenous RNA network of endometrial carcinoma: A comprehensive analysis.J Cell Biochem. 2019 Sep;120(9):15648-15660. doi: 10.1002/jcb.28831. Epub 2019 May 5.
121	Expression of NR1H3 in endometrial carcinoma and its effect on the proliferation of Ishikawa cells in vitro.Onco Targets Ther. 2019 Jan 18;12:685-697. doi: 10.2147/OTT.S180534. eCollection 2019.
122	PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells.Cancer Res. 2001 Jun 1;61(11):4569-75.
123	Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.Virol J. 2018 Apr 10;15(1):65. doi: 10.1186/s12985-018-0975-x.
124	Identification of Potential Crucial Genes Associated With the Pathogenesis and Prognosis of Endometrial Cancer.Front Genet. 2019 Apr 26;10:373. doi: 10.3389/fgene.2019.00373. eCollection 2019.
125	Decreased expression of miR-184 restrains the growth and invasion of endometrial carcinoma cells through CDC25A-dependent Notch signaling pathway.Am J Transl Res. 2019 Feb 15;11(2):755-764. eCollection 2019.
126	Effect of cyclin-dependent kinase 7 silencing on cisplatin sensitivity in endometrial carcinoma cells.Mol Med Rep. 2015 Mar;11(3):1745-51. doi: 10.3892/mmr.2014.2980. Epub 2014 Nov 19.
127	Cyclic changes in the expression of p57(kip2) in human endometrium and its regulation by steroid hormones in endometrial stromal cells in vitro. Reprod Sci. 2012 Jan;19(1):92-101. doi: 10.1177/1933719111414209. Epub 2011 Nov 7.
128	CHEK2, MGMT, SULT1E1 and SULT1A1 polymorphisms and endometrial cancer risk.Twin Res Hum Genet. 2011 Aug;14(4):328-32. doi: 10.1375/twin.14.4.328.
129	Structure, expression and mutational analysis of the hBRAG gene on 10q in the frequently deleted region in human endometrial cancer.Oncol Rep. 2000 Nov-Dec;7(6):1339-42. doi: 10.3892/or.7.6.1339.
130	Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B.Onco Targets Ther. 2018 Oct 1;11:6351-6360. doi: 10.2147/OTT.S174618. eCollection 2018.
131	Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma.Oxid Med Cell Longev. 2015;2015:593658. doi: 10.1155/2015/593658. Epub 2015 Feb 9.
132	Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen.Cancer Med. 2017 Feb;6(2):408-415. doi: 10.1002/cam4.967. Epub 2017 Jan 21.
133	Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR.Mol Carcinog. 2006 Oct;45(10):732-40. doi: 10.1002/mc.20198.
134	Chondroitin sulfate proteoglycan protein is stimulated by interleukin11 and promotes endometrial epithelial cancer cell proliferation and migration.Int J Oncol. 2017 Mar;50(3):798-804. doi: 10.3892/ijo.2017.3848. Epub 2017 Jan 13.
135	Expression of cysteine protease cathepsin L is increased in endometrial cancer and correlates with expression of growth regulatory genes.Cancer Invest. 2012 Jun;30(5):398-403. doi: 10.3109/07357907.2012.672608. Epub 2012 Mar 27.
136	CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-B signaling.Leukemia. 2020 May;34(5):1305-1314. doi: 10.1038/s41375-019-0661-z. Epub 2019 Nov 27.
137	Chemokines mRNA expression in relation to the Macrophage Migration Inhibitory Factor (MIF) mRNA and Vascular Endothelial Growth Factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: a pilot study.Cytokine. 2013 Nov;64(2):509-15. doi: 10.1016/j.cyto.2013.07.024. Epub 2013 Aug 25.
138	Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer.Chem Biol Interact. 2013 Feb 25;202(1-3):210-7. doi: 10.1016/j.cbi.2012.11.012. Epub 2012 Nov 27.
139	Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use.Carcinogenesis. 2007 Oct;28(10):2139-42. doi: 10.1093/carcin/bgm087. Epub 2007 Apr 13.
140	TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma.Pathol Oncol Res. 2020 Jul;26(3):1411-1416. doi: 10.1007/s12253-019-00784-0. Epub 2019 Dec 6.
141	Argininosuccinate Synthase 1-Deficiency Enhances the Cell Sensitivity to Arginine through Decreased DEPTOR Expression in Endometrial Cancer.Sci Rep. 2017 Mar 30;7:45504. doi: 10.1038/srep45504.
142	Diacylglycerol kinase mediates 17--estradiol-induced proliferation, motility, and anchorage-independent growth of Hec-1A endometrial cancer cell line through the G protein-coupled estrogen receptor GPR30.Cell Signal. 2011 Dec;23(12):1988-96. doi: 10.1016/j.cellsig.2011.07.009. Epub 2011 Jul 22.
143	Differential Expression and Clinical Significance of DNA Methyltransferase 3B (DNMT3B), Phosphatase and Tensin Homolog (PTEN) and Human MutL Homologs 1 (hMLH1) in Endometrial Carcinomas.Med Sci Monit. 2017 Feb 21;23:938-947. doi: 10.12659/msm.902267.
144	A two-step strategy for identification of plasma protein biomarkers for endometrial and ovarian cancer.Clin Proteomics. 2018 Dec 1;15:38. doi: 10.1186/s12014-018-9216-y. eCollection 2018.
145	Genetic variants in ER cofactor genes and endometrial cancer risk.PLoS One. 2012;7(8):e42445. doi: 10.1371/journal.pone.0042445. Epub 2012 Aug 2.
146	CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.BMC Cancer. 2019 Apr 29;19(1):401. doi: 10.1186/s12885-019-5556-x.
147	Clinical comparison between neuroendocrine and endometrioid type carcinoma of the uterine corpus.J Gynecol Oncol. 2019 Jul;30(4):e58. doi: 10.3802/jgo.2019.30.e58. Epub 2019 Feb 22.
148	Chronic BDE-47 Exposure Aggravates Malignant Phenotypes and Chemoresistance by Activating ERK Through ER and GPR30 in Endometrial Carcinoma.Front Oncol. 2019 Oct 31;9:1079. doi: 10.3389/fonc.2019.01079. eCollection 2019.
149	Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.Ann Oncol. 2007 Mar;18(3):485-90. doi: 10.1093/annonc/mdl414. Epub 2006 Nov 15.
150	Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma.Tumour Biol. 2005 Jan-Feb;26(1):9-16. doi: 10.1159/000084181. Epub 2005 Feb 28.
151	Antitumor effect of XCT790, an ERR inverse agonist, on ER-negative endometrial cancer cells.Cell Oncol (Dordr). 2019 Apr;42(2):223-235. doi: 10.1007/s13402-019-00423-5. Epub 2019 Jan 31.
152	The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells. Endocrinology. 2002 Mar;143(3):853-67.
153	Clinical and biological significance of EZH2 expression in endometrial cancer.Cancer Biol Ther. 2020;21(2):147-156. doi: 10.1080/15384047.2019.1672455. Epub 2019 Oct 22.
154	Loss of polarity alters proliferation and differentiation in low-grade endometrial cancers by disrupting Notch signaling.PLoS One. 2017 Dec 5;12(12):e0189081. doi: 10.1371/journal.pone.0189081. eCollection 2017.
155	Inactivation of the candidate tumor suppressor par-4 in endometrial cancer.Cancer Res. 2007 Mar 1;67(5):1927-34. doi: 10.1158/0008-5472.CAN-06-2687.
156	Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.Biomed Pharmacother. 2019 Jul;115:108939. doi: 10.1016/j.biopha.2019.108939. Epub 2019 May 9.
157	Clinical value screening, prognostic significance and key pathway identification of miR-204-5p in endometrial carcinoma: A study based on the Cancer Genome Atlas (TCGA), and bioinformatics analysis.Pathol Res Pract. 2019 May;215(5):1003-1011. doi: 10.1016/j.prp.2019.02.007. Epub 2019 Mar 7.
158	Comparative Study of the Effects of Ferrochelatase-siRNA Transfection Mediated by Ultrasound Microbubbles and Polyethyleneimine in Combination with Low-dose ALA to Enhance PpIX Accumulation in Human Endometrial Cancer Xenograft Nude Mice Models.Photochem Photobiol. 2019 Jul;95(4):1045-1051. doi: 10.1111/php.13076. Epub 2019 Feb 11.
159	Long non-coding RNA PVT1 promotes malignancy in human endometrial carcinoma cells through negative regulation of miR-195-5p.Biochim Biophys Acta Mol Cell Res. 2018 Jul 19:S0167-4889(18)30169-1. doi: 10.1016/j.bbamcr.2018.07.008. Online ahead of print.
160	Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells.J Clin Endocrinol Metab. 2003 Feb;88(2):773-80. doi: 10.1210/jc.2002-021062.
161	The fibroblast growth factor 8 family in the female reproductive tract.Reproduction. 2018 Jan;155(1):R53-R62. doi: 10.1530/REP-17-0542.
162	Expressions of the fibroblast growth factor family (FGF-1, -2 and -4) mRNA in endometrial cancers.Tumour Biol. 1996;17(4):226-33. doi: 10.1159/000217984.
163	Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators.J Cancer Res Clin Oncol. 2001 Sep;127(9):545-50. doi: 10.1007/s004320100255.
164	Effects of forkhead box C2 on carcinogenesis and lymphatic metastasis in endometrial carcinoma.Genet Mol Res. 2015 May 25;14(2):5535-47. doi: 10.4238/2015.May.25.5.
165	FTO expression is associated with the occurrence of gastric cancer and prognosis.Oncol Rep. 2017 Oct;38(4):2285-2292. doi: 10.3892/or.2017.5904. Epub 2017 Aug 14.
166	GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer.Int J Gynecol Cancer. 2013 Jul;23(6):1050-5. doi: 10.1097/IGC.0b013e3182959103.
167	GnRH antagonists in the treatment of gynecological and breast cancers.Endocr Relat Cancer. 2003 Jun;10(2):291-9. doi: 10.1677/erc.0.0100291.
168	Endometrial tumors with yolk sac tumor-like morphologic patterns or immunophenotypes: an expanded appraisal.Mod Pathol. 2019 Dec;32(12):1847-1860. doi: 10.1038/s41379-019-0341-6. Epub 2019 Aug 2.
169	Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas.Gynecol Oncol. 2010 May;117(2):239-47. doi: 10.1016/j.ygyno.2010.02.006. Epub 2010 Mar 7.
170	Tumor-associated macrophage-derived CXCL8 could induce ER suppression via HOXB13 in endometrial cancer.Cancer Lett. 2016 Jun 28;376(1):127-36. doi: 10.1016/j.canlet.2016.03.036. Epub 2016 Mar 24.
171	The Role of Hepsin in Endometrial Carcinoma.Appl Immunohistochem Mol Morphol. 2017 Oct;25(9):624-631. doi: 10.1097/PAI.0000000000000352.
172	Blocking 17-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach.J Pathol. 2018 Feb;244(2):203-214. doi: 10.1002/path.5004. Epub 2018 Jan 3.
173	Polymorphisms in genes hydroxysteroid-dehydrogenase-17b type 2 and type 4 and endometrial cancer risk.Gynecol Oncol. 2011 Apr;121(1):54-8. doi: 10.1016/j.ygyno.2010.11.014. Epub 2010 Dec 3.
174	Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique.J Gynecol Obstet Hum Reprod. 2020 Feb;49(2):101652. doi: 10.1016/j.jogoh.2019.101652. Epub 2019 Nov 26.
175	Discovery and validation of methylation markers for endometrial cancer.Int J Cancer. 2014 Oct 15;135(8):1860-8. doi: 10.1002/ijc.28843. Epub 2014 Mar 31.
176	MicroRNA-93-5p/IFNAR1 axis accelerates metastasis of endometrial carcinoma by activating the STAT3 pathway.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5657-5666. doi: 10.26355/eurrev_201907_18302.
177	IR-A/IGF-1R-mediated signals promote epithelial-mesenchymal transition of endometrial carcinoma cells by activating PI3K/AKT and ERK pathways.Cancer Biol Ther. 2019;20(3):295-306. doi: 10.1080/15384047.2018.1529096. Epub 2018 Nov 14.
178	Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors.Int J Cancer. 1994 Nov 1;59(3):307-12. doi: 10.1002/ijc.2910590303.
179	Targeting Interleukin-11 Receptor- Impairs Human Endometrial Cancer Cell Proliferation and Invasion In Vitro and Reduces Tumor Growth and Metastasis In Vivo.Mol Cancer Ther. 2016 Apr;15(4):720-30. doi: 10.1158/1535-7163.MCT-15-0677. Epub 2016 Feb 4.
180	Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma.J Cell Biochem. 2018 Mar;119(3):2545-2555. doi: 10.1002/jcb.26416. Epub 2017 Nov 14.
181	Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B.Cancer Chemother Pharmacol. 2019 Feb;83(2):277-287. doi: 10.1007/s00280-018-3727-0. Epub 2018 Nov 15.
182	Menstrual cyclic change of metastin/GPR54 in endometrium.Med Mol Morphol. 2015 Jun;48(2):76-84. doi: 10.1007/s00795-014-0081-0. Epub 2014 Jun 8.
183	Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers.Immunopharmacology. 1997 Jun;36(2-3):217-20. doi: 10.1016/s0162-3109(97)00024-6.
184	Expression and clinical significance of KLK5-8 in endometrial cancer.Am J Transl Res. 2019 Jul 15;11(7):4180-4191. eCollection 2019.
185	Expression of tumor-associated differentially expressed Gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas.Tumour Biol. 2006;27(5):274-82. doi: 10.1159/000094741. Epub 2006 Jul 28.
186	Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas.Hum Pathol. 2019 Dec;94:40-50. doi: 10.1016/j.humpath.2019.09.005. Epub 2019 Oct 23.
187	LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis.Biomarkers. 2013 Mar;18(2):136-43. doi: 10.3109/1354750X.2012.752526. Epub 2013 Jan 11.
188	Long non-coding RNA LINC00672 contributes to p53 protein-mediated gene suppression and promotes endometrial cancer chemosensitivity. J Biol Chem. 2017 Apr 7;292(14):5801-5813. doi: 10.1074/jbc.M116.758508. Epub 2017 Feb 23.
189	The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer.Cancer Biomark. 2019;24(3):315-324. doi: 10.3233/CBM-181942.
190	Variants in DENND1A and LHCGR are associated with endometrioid adenocarcinoma.Gynecol Oncol. 2012 Nov;127(2):403-5. doi: 10.1016/j.ygyno.2012.08.007. Epub 2012 Aug 14.
191	Immune inhibitory receptor LILRB2 is critical for the endometrial cancer progression.Biochem Biophys Res Commun. 2018 Nov 17;506(1):243-250. doi: 10.1016/j.bbrc.2018.09.114. Epub 2018 Oct 19.
192	A novel role for placental leucine aminopeptidase (P-LAP) as a determinant of chemoresistance in endometrial carcinoma cells.Int J Cancer. 2006 Mar 15;118(6):1390-4. doi: 10.1002/ijc.21509.
193	miR-522 facilitates the prosperities of endometrial carcinoma cells by directly binding to monoamine oxidase B.Kaohsiung J Med Sci. 2019 Oct;35(10):598-606. doi: 10.1002/kjm2.12107. Epub 2019 Jul 4.
194	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.Gynecol Oncol. 2019 Dec;155(3):420-428. doi: 10.1016/j.ygyno.2019.09.024. Epub 2019 Oct 15.
195	Novel breast cancer risk alleles and endometrial cancer risk.Int J Cancer. 2008 Dec 15;123(12):2961-4. doi: 10.1002/ijc.23862.
196	Knocking down of LINC01220 inhibits proliferation and induces apoptosis of endometrial carcinoma through silencing MAPK11.Biosci Rep. 2019 Jul 25;39(7):BSR20181794. doi: 10.1042/BSR20181794. Print 2019 Jul 31.
197	Effect of monoacylglycerol lipase on the tumor growth in endometrial cancer.J Obstet Gynaecol Res. 2019 Oct;45(10):2043-2054. doi: 10.1111/jog.14070. Epub 2019 Jul 29.
198	Gene Promoter Methylation in Endometrial Carcinogenesis.Pathol Oncol Res. 2019 Apr;25(2):659-667. doi: 10.1007/s12253-018-0489-2. Epub 2018 Nov 14.
199	SPOCK2 Affects the Biological Behavior of Endometrial Cancer Cells by Regulation of MT1-MMP and MMP2.Reprod Sci. 2019 Mar 4:1933719119834341. doi: 10.1177/1933719119834341. Online ahead of print.
200	The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1.Int J Cancer. 2011 Oct 15;129(8):2042-9. doi: 10.1002/ijc.25856. Epub 2011 Mar 4.
201	Multiple loci identified in a genome-wide association study of prostate cancer.Nat Genet. 2008 Mar;40(3):310-5. doi: 10.1038/ng.91. Epub 2008 Feb 10.
202	Long Non-Coding RNAs in Endometrial Carcinoma.Int J Mol Sci. 2015 Nov 4;16(11):26463-72. doi: 10.3390/ijms161125962.
203	Deep Infiltrating Endometriosis and Endometrial Adenocarcinoma Express High Levels of Myostatin and Its Receptors Messenger RNAs.Reprod Sci. 2017 Dec;24(12):1577-1582. doi: 10.1177/1933719117698579. Epub 2017 Mar 27.
204	Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.Hum Cell. 2017 Jul;30(3):209-215. doi: 10.1007/s13577-017-0169-7. Epub 2017 Apr 5.
205	Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH.Int J Cancer. 2016 Oct 1;139(7):1557-63. doi: 10.1002/ijc.30197. Epub 2016 Jun 2.
206	Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers.Nat Genet. 2016 Feb;48(2):176-82. doi: 10.1038/ng.3470. Epub 2015 Dec 14.
207	Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers.J Steroid Biochem Mol Biol. 2007 May;104(3-5):237-40. doi: 10.1016/j.jsbmb.2007.03.007. Epub 2007 Mar 15.
208	Expression of NRP-1 and NRP-2 in Endometrial Cancer.Curr Pharm Biotechnol. 2019;20(3):254-260. doi: 10.2174/1389201020666190219121602.
209	Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer.Anticancer Res. 2019 Feb;39(2):585-590. doi: 10.21873/anticanres.13151.
210	Cloning and functional expression of the hNPY Y5 receptor in human endometrial cancer (HEC-1B) cells.Can J Physiol Pharmacol. 2000 Feb;78(2):134-42.
211	Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.Gynecol Oncol. 2019 Jul;154(1):218-227. doi: 10.1016/j.ygyno.2019.04.678. Epub 2019 Apr 30.
212	Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome.Virchows Arch. 2017 Oct;471(4):521-530. doi: 10.1007/s00428-017-2215-y. Epub 2017 Aug 24.
213	Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling. Am J Pathol. 2010 Nov;177(5):2495-508. doi: 10.2353/ajpath.2010.100026.
214	Expression and responsiveness of P2Y2 receptors in human endometrial cancer cell lines.J Clin Endocrinol Metab. 1999 Nov;84(11):4085-91. doi: 10.1210/jcem.84.11.6119.
215	1,25(OH)2D3 Induces Actin Depolymerization in Endometrial Carcinoma Cells by Targeting RAC1 and PAK1.Cell Physiol Biochem. 2016;40(6):1455-1464. doi: 10.1159/000453197. Epub 2016 Dec 20.
216	Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers.Oncotarget. 2017 Jul 31;8(40):68530-68541. doi: 10.18632/oncotarget.19708. eCollection 2017 Sep 15.
217	Proprotein convertases in post-menopausal endometrial cancer: distinctive regulation and non-invasive diagnosis.Biochem Biophys Res Commun. 2012 Mar 23;419(4):809-14. doi: 10.1016/j.bbrc.2012.02.111. Epub 2012 Feb 27.
218	Over-expression of platelet-derived growth factor-D promotes tumor growth and invasion in endometrial cancer.Int J Mol Sci. 2014 Mar 18;15(3):4780-94. doi: 10.3390/ijms15034780.
219	Pepsinogen C expression, regulation and its relationship with cancer.Cancer Cell Int. 2017 May 23;17:57. doi: 10.1186/s12935-017-0426-6. eCollection 2017.
220	Negative regulation of AMPK1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer.Oncogene. 2019 Sep;38(38):6537-6549. doi: 10.1038/s41388-019-0898-z. Epub 2019 Jul 29.
221	Individualised proteome profiling of human endometrial tumours improves detection of new prognostic markers.Br J Cancer. 2013 Aug 6;109(3):704-13. doi: 10.1038/bjc.2013.359. Epub 2013 Jul 9.
222	Laparoendoscopic Single-Site Sentinel Lymph Node Detection in Endometrial Cancer.J Minim Invasive Gynecol. 2018 Jul-Aug;25(5):776. doi: 10.1016/j.jmig.2017.10.035. Epub 2017 Nov 13.
223	Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.Front Oncol. 2019 Mar 4;9:123. doi: 10.3389/fonc.2019.00123. eCollection 2019.
224	Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer.Oncol Lett. 2018 Apr;15(4):5111-5118. doi: 10.3892/ol.2018.7909. Epub 2018 Jan 31.
225	Serum Prolactin Contributes to Enhancing Prolactin Receptor and pJAK2 in Type I Endometrial Cancer Cells in Young Women Without Insulin Resistance.Int J Gynecol Pathol. 2019 Jul;38(4):318-325. doi: 10.1097/PGP.0000000000000527.
226	Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer.Oncotarget. 2016 Jun 28;7(26):39885-39893. doi: 10.18632/oncotarget.9414.
227	Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1.Oncotarget. 2017 Dec 15;8(70):115360-115369. doi: 10.18632/oncotarget.23264. eCollection 2017 Dec 29.
228	RICTOR expression in esophageal squamous cell carcinoma and its clinical significance.Med Oncol. 2017 Mar;34(3):32. doi: 10.1007/s12032-017-0894-5. Epub 2017 Jan 28.
229	ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.Gynecol Oncol. 2018 Mar;148(3):576-584. doi: 10.1016/j.ygyno.2018.01.025. Epub 2018 Feb 1.
230	Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.Clin Cancer Res. 2011 Apr 15;17(8):2120-9. doi: 10.1158/1078-0432.CCR-10-2668. Epub 2011 Mar 3.
231	Expression of Laminin Receptor 1 in Normal, Hyperplastic, and Malignant Endometrium.Int J Gynecol Pathol. 2019 Jul;38(4):326-334. doi: 10.1097/PGP.0000000000000535.
232	Construction of a Competitive Endogenous RNA Network in Uterine Corpus Endometrial Carcinoma.Med Sci Monit. 2019 Oct 25;25:7998-8010. doi: 10.12659/MSM.915798.
233	Estrogenrelated receptor promotes the migration and metastasis of endometrial cancer cells by targeting S100A4.Oncol Rep. 2018 Aug;40(2):823-832. doi: 10.3892/or.2018.6471. Epub 2018 Jun 4.
234	Expression of SCUBE2 gene declines in high grade endometrial cancer and associates with expression of steroid hormone receptors and tumor suppressor PTEN.Gynecol Endocrinol. 2013 Dec;29(12):1031-5. doi: 10.3109/09513590.2013.829441. Epub 2013 Sep 20.
235	Endometrial cancer surveillance adherence reduces utilization and subsequent costs.Gynecol Oncol. 2017 Sep;146(3):514-518. doi: 10.1016/j.ygyno.2017.06.024. Epub 2017 Jul 19.
236	A small compound spindlactone A sensitizes human endometrial cancer cells to TRAIL-induced apoptosis via the inhibition of NAD(P)H dehydrogenase quinone 1.Onco Targets Ther. 2018 Jun 21;11:3609-3617. doi: 10.2147/OTT.S165723. eCollection 2018.
237	CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.J Immunol Res. 2018 Nov 7;2018:6156757. doi: 10.1155/2018/6156757. eCollection 2018.
238	Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium.Oncotarget. 2016 Jan 12;7(2):1144-54. doi: 10.18632/oncotarget.6691.
239	ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma.Oncogenesis. 2017 Jul 31;6(7):e367. doi: 10.1038/oncsis.2017.70.
240	Negative Effect of Ellagic Acid on Cytosolic pH Regulation and Glycolytic Flux in Human Endometrial Cancer Cells.Cell Physiol Biochem. 2017;41(6):2374-2382. doi: 10.1159/000475655. Epub 2017 Apr 27.
241	MicroRNA-449a Inhibits Tumor Metastasis through AKT/ERK1/2 Inactivation by Targeting Steroid Receptor Coactivator (SRC) in Endometrial Cancer.J Cancer. 2019 Jan 1;10(2):547-555. doi: 10.7150/jca.27748. eCollection 2019.
242	Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation.Life Sci. 2019 Jan 15;217:70-80. doi: 10.1016/j.lfs.2018.11.037. Epub 2018 Nov 16.
243	SOX15 regulates proliferation and migration of endometrial cancer cells.Biosci Rep. 2017 Oct 17;37(5):BSR20171045. doi: 10.1042/BSR20171045. Print 2017 Oct 31.
244	Stanniocalcin-2 May Be a Potentially Valuable Prognostic Marker in Endometrial Cancer: a Preliminary Study.Pathol Oncol Res. 2019 Apr;25(2):751-757. doi: 10.1007/s12253-018-00576-y. Epub 2019 Jan 19.
245	Six-transmembrane epithelial antigen of the prostate 1 is associated with tumor invasion and migration in endometrial carcinomas.J Cell Biochem. 2019 Jul;120(7):11172-11189. doi: 10.1002/jcb.28393. Epub 2019 Feb 3.
246	LOC134466 methylation promotes oncogenesis of endometrial carcinoma through LOC134466/hsa-miR-196a-5p/TAC1 axis.Aging (Albany NY). 2018 Nov 28;10(11):3353-3370. doi: 10.18632/aging.101644.
247	Telomere length and genetic analyses in population-based studies of endometrial cancer risk.Cancer. 2010 Sep 15;116(18):4275-82. doi: 10.1002/cncr.25328.
248	Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9.J Biol Chem. 2007 Feb 16;282(7):4794-4802. doi: 10.1074/jbc.M608497200. Epub 2006 Dec 6.
249	Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level.Int J Mol Sci. 2018 Jun 22;19(7):1848. doi: 10.3390/ijms19071848.
250	TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway.Cancer Lett. 2010 Aug 1;294(1):91-100. doi: 10.1016/j.canlet.2010.01.027. Epub 2010 Feb 26.
251	Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.BMC Cancer. 2014 Nov 26;14:884. doi: 10.1186/1471-2407-14-884.
252	Topoisomerase II binding protein 1 c.*229C>T (rs115160714) gene polymorphism and endometrial cancer risk.Pathol Oncol Res. 2014 Jul;20(3):597-602. doi: 10.1007/s12253-013-9737-7. Epub 2013 Dec 18.
253	MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2.Cell Cycle. 2018;17(10):1268-1278. doi: 10.1080/15384101.2018.1475829. Epub 2018 Jul 23.
254	RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations.Pathol Int. 2012 May;62(5):324-30. doi: 10.1111/j.1440-1827.2012.02797.x. Epub 2012 Mar 27.
255	miR-214-3p inhibits epithelial-to-mesenchymal transition and metastasis of endometrial cancer cells by targeting TWIST1.Onco Targets Ther. 2019 Nov 18;12:9449-9458. doi: 10.2147/OTT.S181037. eCollection 2019.
256	Genetic variation in CYP17A1 and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California.Int J Cancer. 2010 Feb 1;126(3):790-5. doi: 10.1002/ijc.24792.
257	Alternative splicing of VEGFA is regulated by RBM10 in endometrial cancer.Kaohsiung J Med Sci. 2020 Jan;36(1):13-19. doi: 10.1002/kjm2.12127. Epub 2019 Oct 6.
258	VISTA expressed in tumour cells regulates T cell function.Br J Cancer. 2019 Jan;120(1):115-127. doi: 10.1038/s41416-018-0313-5. Epub 2018 Nov 9.
259	Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.Gynecol Oncol. 2017 Jun;145(3):446-452. doi: 10.1016/j.ygyno.2017.03.006. Epub 2017 Mar 25.
260	Identification of ERF-1 as a member of the AP2 transcription factor family.Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4342-7. doi: 10.1073/pnas.94.9.4342.
261	Long Non-coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma.Front Oncol. 2019 Jan 29;9:27. doi: 10.3389/fonc.2019.00027. eCollection 2019.
262	A polymerase-chain-reaction assay for the specific identification of transcripts encoded by individual carcinoembryonic antigen (CEA)-gene-family members.Int J Cancer. 1993 Sep 9;55(2):311-9. doi: 10.1002/ijc.2910550223.
263	In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.Int J Mol Sci. 2016 Sep 9;17(9):1525. doi: 10.3390/ijms17091525.
264	Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.Biomed Pharmacother. 2019 May;113:108712. doi: 10.1016/j.biopha.2019.108712. Epub 2019 Mar 6.
265	Quantitative RT-PCR Assay for Detecting Lymph Node Metastasis in Endometrial Cancer: A Preliminary Study.Oncology. 2019;96(4):179-182. doi: 10.1159/000493485. Epub 2018 Nov 14.
266	Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.Cancer Cell. 2017 Dec 11;32(6):761-776.e6. doi: 10.1016/j.ccell.2017.11.006.
267	Identification of new fusion genes and their clinical significance in endometrial cancer.Chin Med J (Engl). 2019 Jun 5;132(11):1314-1321. doi: 10.1097/CM9.0000000000000203.
268	K-ras activation in neoplasms of the human female reproductive tract.Cancer Res. 1990 Oct 1;50(19):6139-45.
269	Reversed glucose and fatty acids transporter expression in human endometrial cancer.Horm Metab Res. 2012 Jun;44(6):436-41. doi: 10.1055/s-0031-1301301. Epub 2012 Feb 20.
270	Knockout of glucose transporter GLUT6 has minimal effects on whole body metabolic physiology in mice.Am J Physiol Endocrinol Metab. 2018 Aug 1;315(2):E286-E293. doi: 10.1152/ajpendo.00082.2018. Epub 2018 Apr 17.
271	Application of laser capture microdissection and differential display technique for screening of pathogenic genes involved in endometrial carcinoma.Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1224-30. doi: 10.1111/j.1525-1438.2007.00947.x. Epub 2007 Apr 19.
272	Preoperative frailty is a risk factor for non-home discharge in patients undergoing surgery for endometrial cancer.J Geriatr Oncol. 2018 Sep;9(5):513-515. doi: 10.1016/j.jgo.2018.02.005. Epub 2018 Mar 9.
273	Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.Oncotarget. 2016 Mar 1;7(9):10363-72. doi: 10.18632/oncotarget.7004.
274	STAR and AKR1B10 are down-regulated in high-grade endometrial cancer.J Steroid Biochem Mol Biol. 2017 Jul;171:43-53. doi: 10.1016/j.jsbmb.2017.02.015. Epub 2017 Feb 21.
275	Do microsatellite instability profiles really differ between colorectal and endometrial tumors?.Genes Chromosomes Cancer. 2009 Jul;48(7):552-7. doi: 10.1002/gcc.20664.
276	Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.Tohoku J Exp Med. 2007 May;212(1):1-12. doi: 10.1620/tjem.212.1.
277	Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT.Mol Cell Endocrinol. 2011 Jan 1;331(1):158-67. doi: 10.1016/j.mce.2010.09.011. Epub 2010 Sep 29.
278	-Glutamyl cyclotransferase contributes to endometrial carcinoma malignant progression and upregulation of PD-L1 expression during activation of epithelial-mesenchymal transition.Int Immunopharmacol. 2020 Apr;81:106039. doi: 10.1016/j.intimp.2019.106039. Epub 2019 Nov 19.
279	Integrated eicosanoid lipidomics and gene expression reveal decreased prostaglandin catabolism and increased 5-lipoxygenase expression in aggressive subtypes of endometrial cancer.J Pathol. 2019 Jan;247(1):21-34. doi: 10.1002/path.5160. Epub 2018 Nov 27.
280	AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma.Oncotarget. 2015 Sep 22;6(28):26373-87. doi: 10.18632/oncotarget.4708.
281	The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism.Chem Biol Interact. 2015 Jun 5;234:309-19. doi: 10.1016/j.cbi.2014.11.015. Epub 2014 Nov 28.
282	Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer.Carcinogenesis. 2010 Sep;31(9):1620-6. doi: 10.1093/carcin/bgq124. Epub 2010 Jun 16.
283	Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells.Oncol Rep. 2012 May;27(5):1488-96. doi: 10.3892/or.2012.1670. Epub 2012 Feb 2.
284	A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers.Clin Cancer Res. 2006 Jan 1;12(1):191-7. doi: 10.1158/1078-0432.CCR-05-1206.
285	Utility of diffusion-weighted imaging in association with pathologic upgrading in biopsy-proven grade I endometrial cancer.J Magn Reson Imaging. 2020 Jan;51(1):117-123. doi: 10.1002/jmri.26840. Epub 2019 Jun 17.
286	The relationships between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer.Folia Histochem Cytobiol. 2014;52(3):187-94. doi: 10.5603/FHC.2014.0022.
287	Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection.Gynecol Oncol. 2020 Feb;156(2):387-392. doi: 10.1016/j.ygyno.2019.11.028. Epub 2019 Nov 28.
288	Intestinal differentiated mucinous adenocarcinoma of the endometrium with sporadic MSI high status: a case report.Diagn Pathol. 2017 May 12;12(1):39. doi: 10.1186/s13000-017-0629-0.
289	Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer.Curr Pharm Biotechnol. 2020;21(1):52-59. doi: 10.2174/1389201020666190918104105.
290	CTCF Expression is Essential for Somatic Cell Viability and Protection Against Cancer.Int J Mol Sci. 2018 Nov 30;19(12):3832. doi: 10.3390/ijms19123832.
291	CTHRC1 promotes M2-like macrophage recruitment and myometrial invasion in endometrial carcinoma by integrin-Akt signaling pathway.Clin Exp Metastasis. 2019 Aug;36(4):351-363. doi: 10.1007/s10585-019-09971-4. Epub 2019 May 22.
292	Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer.Front Oncol. 2019 Nov 6;9:1147. doi: 10.3389/fonc.2019.01147. eCollection 2019.
293	The R156R ERCC2 polymorphism as a risk factor of endometrial cancer.Tumour Biol. 2016 Feb;37(2):2171-6. doi: 10.1007/s13277-015-4040-8. Epub 2015 Sep 9.
294	Upregulation of syncytin-1 promotes invasion and metastasis by activating epithelial-mesenchymal transition-related pathway in endometrial carcinoma.Onco Targets Ther. 2018 Dec 17;12:31-40. doi: 10.2147/OTT.S191041. eCollection 2019.
295	gamma-H2AX: Can it be established as a classical cancer prognostic factor?.Tumour Biol. 2017 Mar;39(3):1010428317695931. doi: 10.1177/1010428317695931.
296	Tumor-suppressor role of miR-139-5p in endometrial cancer.Cancer Cell Int. 2018 Apr 2;18:51. doi: 10.1186/s12935-018-0545-8. eCollection 2018.
297	HNRNP G and HTRA2-BETA1 regulate estrogen receptor alpha expression with potential impact on endometrial cancer.BMC Cancer. 2015 Feb 27;15:86. doi: 10.1186/s12885-015-1088-1.
298	Krppel-like factor 9 loss-of-expression in human endometrial carcinoma links altered expression of growth-regulatory genes with aberrant proliferative response to estrogen.Biol Reprod. 2011 Aug;85(2):378-85. doi: 10.1095/biolreprod.110.090654. Epub 2011 May 4.
299	Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer.Oncotarget. 2012 Dec;3(12):1546-56. doi: 10.18632/oncotarget.667.
300	Increased expression of human luteinizing hormone/human chorionic gonadotropin receptor mRNA in human endometrial cancer.Mol Cell Probes. 2002 Aug;16(4):269-75. doi: 10.1006/mcpr.2002.0421.
301	Loss of tricellular tight junction protein LSR promotes cell invasion and migration via upregulation of TEAD1/AREG in human endometrial cancer.Sci Rep. 2017 Jan 10;7:37049. doi: 10.1038/srep37049.
302	Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma.Gene. 2019 Apr 30;694:76-82. doi: 10.1016/j.gene.2018.12.076. Epub 2019 Jan 16.
303	Loss of MDC1 in Endometrial Carcinoma Is Associated With Loss of MRN Complex and MMR Deficiency.Anticancer Res. 2019 Dec;39(12):6547-6553. doi: 10.21873/anticanres.13870.
304	Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability.Am J Pathol. 2002 Jun;160(6):1953-8. doi: 10.1016/S0002-9440(10)61144-3.
305	Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease.Proc Natl Acad Sci U S A. 2009 May 26;106(21):8677-82. doi: 10.1073/pnas.0903632106. Epub 2009 May 13.
306	Nucleobindin 2 (NUCB2) in human endometrial carcinoma: a potent prognostic factor associated with cell proliferation and migration.Endocr J. 2016;63(3):287-99. doi: 10.1507/endocrj.EJ15-0490. Epub 2016 Feb 4.
307	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses.Cancer Med. 2018 May;7(5):1978-1987. doi: 10.1002/cam4.1445. Epub 2018 Apr 2.
308	Downregulation of PDCD4 induced by progesterone is mediated by the PI3K/AKT signaling pathway in human endometrial cancer cells.Oncol Rep. 2019 Aug;42(2):849-856. doi: 10.3892/or.2019.7202. Epub 2019 Jun 18.
309	CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.Oncogene. 2008 Apr 17;27(18):2513-24. doi: 10.1038/sj.onc.1210924. Epub 2007 Nov 5.
310	PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma.Mol Med. 2019 Mar 29;25(1):11. doi: 10.1186/s10020-019-0079-0.
311	RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer.Biochem Biophys Res Commun. 2017 Jul 22;489(2):96-102. doi: 10.1016/j.bbrc.2017.05.095. Epub 2017 May 18.
312	Endocrine gland-derived vascular endothelial growth factor is expressed in human peri-implantation endometrium, but not in endometrial carcinoma.Endocrinology. 2006 Jan;147(1):88-95. doi: 10.1210/en.2005-0543. Epub 2005 Oct 6.
313	Role of ribosomal protein mutations in tumor development (Review).Int J Oncol. 2016 Apr;48(4):1313-24. doi: 10.3892/ijo.2016.3387. Epub 2016 Feb 9.
314	The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.Gynecol Oncol. 2018 Mar;148(3):485-490. doi: 10.1016/j.ygyno.2017.12.026. Epub 2017 Dec 28.
315	Para-aortic Lymph Node Invasion in High-risk Endometrial Cancer: Performance of (18)FDG PET-CT.Anticancer Res. 2019 Feb;39(2):619-625. doi: 10.21873/anticanres.13155.
316	NSSR1 is regulated by testosterone in the mouse uterus and extensively expressed in endometrial carcinoma.Tumour Biol. 2011 Apr;32(2):359-66. doi: 10.1007/s13277-010-0128-3. Epub 2010 Nov 12.
317	Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer.Tumour Biol. 2016 Sep;37(9):12203-12211. doi: 10.1007/s13277-016-5087-x. Epub 2016 May 26.
318	Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.Oncol Rep. 2013 Dec;30(6):2937-44. doi: 10.3892/or.2013.2790. Epub 2013 Oct 8.
319	Nucleophosmin/B23 is a negative regulator of estrogen receptor expression via AP2 in endometrial cancer cells.Oncotarget. 2016 Sep 13;7(37):60038-60052. doi: 10.18632/oncotarget.11048.
320	Significance of TGFBR3 allelic loss in the deregulation of TGF signaling in primary human endometrial carcinomas.Oncol Rep. 2016 Feb;35(2):932-8. doi: 10.3892/or.2015.4400. Epub 2015 Nov 5.
321	Silencing of the icb-1 gene inhibits the induction of differentiation-associated genes by vitamin D3 and all-trans retinoic acid in gynecological cancer cells.Int J Mol Med. 2011 Jul;28(1):121-7. doi: 10.3892/ijmm.2011.663. Epub 2011 Mar 31.
322	Expressions and significances of TTF-1 and PTEN in early endometrial cancer.Eur Rev Med Pharmacol Sci. 2017 Jul;21(3 Suppl):20-26.
323	AQP2 is regulated by estradiol in human endometrium and is associated with spheroid attachment invitro.Mol Med Rep. 2019 Aug;20(2):1306-1312. doi: 10.3892/mmr.2019.10338. Epub 2019 Jun 5.
324	Imup-1 and imup-2 overexpression in endometrial carcinoma in Korean and Japanese populations.Anticancer Res. 2008 Mar-Apr;28(2A):865-71.
325	Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.Gynecol Oncol. 2009 Jan;112(1):229-34. doi: 10.1016/j.ygyno.2008.09.039. Epub 2008 Nov 12.
326	Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings.Clin Epigenetics. 2019 Nov 28;11(1):170. doi: 10.1186/s13148-019-0765-3.
327	Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor .Int J Oncol. 2015 Jul;47(1):106-14. doi: 10.3892/ijo.2015.2988. Epub 2015 May 6.
328	Sirtuin-7 knockdown inhibits the growth of endometrial cancer cells by inducing apoptosis via the NF-B signaling pathway.Oncol Lett. 2019 Jan;17(1):937-943. doi: 10.3892/ol.2018.9698. Epub 2018 Nov 14.
329	Apolipoprotein D expression in retinoblastoma.Ophthalmic Res. 2003 Mar-Apr;35(2):111-6. doi: 10.1159/000069130.
330	Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.Am J Surg Pathol. 2018 Jan;42(1):76-83. doi: 10.1097/PAS.0000000000000941.
331	Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.Cancer Biol Ther. 2008 Feb;7(2):180-88. doi: 10.4161/cbt.7.2.5253. Epub 2007 Nov 15.
332	Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. Oncol Rep. 2018 Apr;39(4):1919-1929.
333	Mitochondrial supercomplex assembly promotes breast and endometrial tumorigenesis by metabolic alterations and enhanced hypoxia tolerance.Nat Commun. 2019 Sep 11;10(1):4108. doi: 10.1038/s41467-019-12124-6.
334	EMP2 is a novel therapeutic target for endometrial cancer stem cells.Oncogene. 2017 Oct 19;36(42):5793-5807. doi: 10.1038/onc.2017.142. Epub 2017 Jun 12.
335	Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ER in Tamoxifen-Associated Endometrial Carcinomas.Cancer Res. 2016 Jul 1;76(13):3773-84. doi: 10.1158/0008-5472.CAN-14-1813. Epub 2016 May 6.
336	Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma.Eur J Endocrinol. 2005 Feb;152(2):277-84. doi: 10.1530/eje.1.01849.
337	Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: an international, multicenter, prospective study.Cancer. 2015 Mar 1;121(5):688-96. doi: 10.1002/cncr.29106. Epub 2014 Nov 5.
338	New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes.Cancer Discov. 2011 Jul;1(2):106-7. doi: 10.1158/2159-8290.CD-11-0116.
339	RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomas.Int J Cancer. 2006 Aug 15;119(4):801-6. doi: 10.1002/ijc.21912.
340	Rap1GAP inhibits tumor progression in endometrial cancer.Biochem Biophys Res Commun. 2017 Apr 1;485(2):476-483. doi: 10.1016/j.bbrc.2017.02.044. Epub 2017 Feb 11.
341	Mammaglobin B expression in human endometrial cancer.Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6. doi: 10.1111/j.1525-1438.2007.01137.x. Epub 2007 Nov 16.
342	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.J Clin Invest. 2011 Nov;121(11):4257-67. doi: 10.1172/JCI58509. Epub 2011 Oct 3.
343	Changes in Expression Pattern of SEMA3F Depending on Endometrial Cancer Grade - Pilot Study.Curr Pharm Biotechnol. 2019;20(9):727-732. doi: 10.2174/1389201020666190619145655.
344	MicroRNA-23a inhibits endometrial cancer cell development by targeting SIX1.Oncol Lett. 2019 Oct;18(4):3792-3802. doi: 10.3892/ol.2019.10694. Epub 2019 Jul 31.
345	Expression and potential role of SNF5 in endometrial carcinoma.BMC Womens Health. 2019 Jan 25;19(1):16. doi: 10.1186/s12905-019-0718-1.
346	Identification of chimeric TSNAX-DISC1 resulting from intergenic splicing in endometrial carcinoma through high-throughput RNA sequencing.Carcinogenesis. 2014 Dec;35(12):2687-97. doi: 10.1093/carcin/bgu201. Epub 2014 Sep 19.
347	AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis.EMBO J. 2012 Oct 17;31(20):3961-75. doi: 10.1038/emboj.2012.236. Epub 2012 Aug 21.
348	Can ABCF2 protein expression predict the prognosis of uterine cancer?.Br J Cancer. 2008 Nov 18;99(10):1651-5. doi: 10.1038/sj.bjc.6604734.
349	Oncogenic role of ABHD5 in endometrial cancer.Cancer Manag Res. 2019 Mar 14;11:2139-2150. doi: 10.2147/CMAR.S188648. eCollection 2019.
350	Acid phosphatase locus 1 genetic polymorphism and cancer grading.Am J Med Sci. 2012 Jul;344(1):32-4. doi: 10.1097/MAJ.0b013e31823e5cfa.
351	Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis.Sci Rep. 2017 Aug 18;7(1):8803. doi: 10.1038/s41598-017-09169-2.
352	MiR-218 suppresses metastasis and invasion of endometrial cancer via negatively regulating ADD2.Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1408-1417. doi: 10.26355/eurrev_201902_17097.
353	G-protein coupled receptor 64 (GPR64) acts as a tumor suppressor in endometrial cancer.BMC Cancer. 2019 Aug 14;19(1):810. doi: 10.1186/s12885-019-5998-1.
354	Adenylosuccinate lyase enhances aggressiveness of endometrial cancer by increasing killer cell lectin-like receptor C3 expression by fumarate.Lab Invest. 2018 Apr;98(4):449-461. doi: 10.1038/s41374-017-0017-0. Epub 2018 Feb 21.
355	Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer.BMC Cancer. 2015 Apr 12;15:275. doi: 10.1186/s12885-015-1286-x.
356	AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways.Reprod Sci. 2011 Sep;18(9):832-41. doi: 10.1177/1933719111398501.
357	Anti-Mllerian Hormone Expression in Endometrial Cancer Tissue.Int J Mol Sci. 2019 Mar 15;20(6):1325. doi: 10.3390/ijms20061325.
358	Estrogen receptor alpha activates MAPK signaling pathway to promote the development of endometrial cancer.J Cell Biochem. 2019 Oct;120(10):17593-17601. doi: 10.1002/jcb.29027. Epub 2019 May 29.
359	A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate.Oncotarget. 2017 Nov 30;8(65):109536-109545. doi: 10.18632/oncotarget.22725. eCollection 2017 Dec 12.
360	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer.Gynecol Oncol. 2017 Nov;147(2):371-374. doi: 10.1016/j.ygyno.2017.09.005. Epub 2017 Sep 22.
361	SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.BMC Med Genet. 2015 Aug 21;16:67. doi: 10.1186/s12881-015-0216-8.
362	Expression and clinical significance of ARTN and MMP-9 in endometrial carcinoma.J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):879-887.
363	Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: a meta-analysis.Int J Gynecol Cancer. 2011 Feb;21(2):323-31. doi: 10.1097/IGC.0b013e31820575c0.
364	Expression of renin-angiotensin system (RAS) components in endometrial cancer.Endocr Connect. 2017 Jan;6(1):9-19. doi: 10.1530/EC-16-0082. Epub 2016 Dec 12.
365	Abnormalities of the APC/beta-catenin pathway in endometrial cancer.Oncogene. 2002 Nov 14;21(52):7981-90. doi: 10.1038/sj.onc.1205924.
366	BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.Eur J Hum Genet. 2006 Feb;14(2):167-72. doi: 10.1038/sj.ejhg.5201542.
367	Expression of gastrin-releasing peptide receptors in endometrial cancer.J Am Coll Surg. 2003 Jun;196(6):898-904. doi: 10.1016/S1072-7515(03)00290-4.
368	No evidence for BCL10 mutation in endometrial cancers with microsatellite instability.Hum Mutat. 2001 Feb;17(2):117-21. doi: 10.1002/1098-1004(200102)17:2<117::AID-HUMU3>3.0.CO;2-D.
369	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.Int J Cancer. 2017 Apr 1;140(7):1551-1563. doi: 10.1002/ijc.30573. Epub 2017 Feb 2.
370	Mutual suppression between BHLHE40/BHLHE41 and the MIR301B-MIR130B cluster is involved in epithelial-to-mesenchymal transition of endometrial cancer cells.Oncotarget. 2019 Jul 23;10(45):4640-4654. doi: 10.18632/oncotarget.27061. eCollection 2019 Jul 23.
371	Colorectal and Endometrial Cancer Risk and Age at Diagnosis in BLMAsh Mutation Carriers.Isr Med Assoc J. 2017 Jun;19(6):365-367.
372	Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.Clin Obstet Gynecol. 2020 Mar;63(1):64-73. doi: 10.1097/GRF.0000000000000499.
373	The Role of Sialyl-Tn in Cancer.Int J Mol Sci. 2016 Feb 24;17(3):275. doi: 10.3390/ijms17030275.
374	Expression of calbindin-D28k is inversely correlated with proapototic gene expression in hydrogen peroxide-induced cell death in endometrial cancer cells.Int J Oncol. 2011 Apr;38(4):1059-66. doi: 10.3892/ijo.2011.916. Epub 2011 Jan 21.
375	CaMKIV expression is associated with clinical stage and PCNA-labeling index in endometrial carcinoma.Int J Mol Med. 2003 Feb;11(2):181-6.
376	The prognostic significance of positive peritoneal cytology in endometrial cancer and its correlations with L1-CAM biomarker.Surg Oncol. 2019 Mar;28:151-157. doi: 10.1016/j.suronc.2019.01.001. Epub 2019 Jan 5.
377	Survival implications of time to surgical treatment of endometrial cancers.Am J Obstet Gynecol. 2017 Mar;216(3):268.e1-268.e18. doi: 10.1016/j.ajog.2016.11.1050. Epub 2016 Dec 9.
378	Genetic polymorphism of PRKCDBP is associated with an increased risk of endometrial cancer.Cancer Invest. 2012 Nov;30(9):642-5. doi: 10.3109/07357907.2012.727054. Epub 2012 Sep 28.
379	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.J Pharmacol Exp Ther. 2018 Mar;364(3):494-503. doi: 10.1124/jpet.117.244129. Epub 2017 Dec 20.
380	Expression of human Biot2 and its potential function on carcinogenesis in endometrial cancer.Acta Obstet Gynecol Scand. 2007;86(12):1503-9. doi: 10.1080/00016340701736946.
381	Effects of expression of exogenous cyclin G1 on proliferation of human endometrial carcinoma cells.Chin J Physiol. 2013 Apr 30;56(2):83-9. doi: 10.4077/CJP.2013.BAA079.
382	Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.Clin Chim Acta. 2019 Feb;489:225-232. doi: 10.1016/j.cca.2018.08.013. Epub 2018 Aug 11.
383	Potential new biomarkers for endometrial cancer.Cancer Cell Int. 2019 Jan 21;19:19. doi: 10.1186/s12935-019-0731-3. eCollection 2019.
384	Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings.Clin Cancer Res. 2017 Jan 1;23(1):263-272. doi: 10.1158/1078-0432.CCR-16-0863. Epub 2016 Aug 9.
385	CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.Gynecol Oncol. 2014 Apr;133(1):83-9. doi: 10.1016/j.ygyno.2013.12.006.
386	CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling.Am J Cancer Res. 2018 May 1;8(5):903-914. eCollection 2018.
387	RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial cancer cells.Oncol Rep. 2012 Jul;28(1):248-54. doi: 10.3892/or.2012.1752. Epub 2012 Apr 2.
388	Long noncoding RNA CHL1-AS1 promotes cell proliferation and migration by sponging miR-6076 to regulate CHL1 expression in endometrial cancer.J Cell Biochem. 2020 Mar;121(3):2655-2663. doi: 10.1002/jcb.29486. Epub 2019 Nov 17.
389	Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer.Mol Carcinog. 2010 Feb;49(2):130-40. doi: 10.1002/mc.20582.
390	Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).Cancer. 2007 Apr 1;109(7):1312-22. doi: 10.1002/cncr.22536.
391	Downregulation of lipolysis-stimulated lipoprotein receptor promotes cell invasion via claudin-1-mediated matrix metalloproteinases in human endometrial cancer.Oncol Lett. 2017 Dec;14(6):6776-6782. doi: 10.3892/ol.2017.7038. Epub 2017 Sep 22.
392	Quantitative DNA methylation analysis of selected genes in endometrial carcinogenesis.Taiwan J Obstet Gynecol. 2015 Oct;54(5):572-9. doi: 10.1016/j.tjog.2015.08.010.
393	miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer.Cancer Res. 2011 Oct 15;71(20):6450-62. doi: 10.1158/0008-5472.CAN-11-0364. Epub 2011 Aug 25.
394	MicroRNA-183 induces epithelial-mesenchymal transition and promotes endometrial cancer cell migration and invasion in by targeting CPEB1.J Cell Biochem. 2018 Nov;119(10):8123-8137. doi: 10.1002/jcb.26763. Epub 2018 Jun 20.
395	CRKL overexpression promotes cell proliferation and inhibits apoptosis in endometrial carcinoma.Oncol Lett. 2017 Jan;13(1):51-56. doi: 10.3892/ol.2016.5394. Epub 2016 Nov 17.
396	Benzotriazole Enhances Cell Invasive Potency in Endometrial Carcinoma Through CTBP1-Mediated Epithelial-Mesenchymal Transition.Cell Physiol Biochem. 2017;44(6):2357-2367. doi: 10.1159/000486123. Epub 2017 Dec 15.
397	HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.Int J Mol Sci. 2013 Nov 18;14(11):22655-77. doi: 10.3390/ijms141122655.
398	Disabled-1 is a large common fragile site gene, inactivated in multiple cancers.Genes Chromosomes Cancer. 2008 Feb;47(2):165-74. doi: 10.1002/gcc.20519.
399	Expression and clinical significance of the transforming growth factor- signalling pathway in endometrial cancer.Histopathology. 2011 Jul;59(1):63-72. doi: 10.1111/j.1365-2559.2011.03892.x.
400	A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer.Oncotarget. 2017 Jan 24;8(4):6043-6056. doi: 10.18632/oncotarget.13464.
401	DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.Cancer Med. 2019 Aug;8(9):4380-4388. doi: 10.1002/cam4.2317. Epub 2019 Jun 18.
402	Expression of DCC and netrin-1 in normal human endometrium and its implication in endometrial carcinogenesis.Gynecol Oncol. 2004 Nov;95(2):281-9. doi: 10.1016/j.ygyno.2004.07.050.
403	Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.Curr Mol Med. 2016;16(3):252-65. doi: 10.2174/1566524016666160225153307.
404	Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
405	Endometrial miR-181a and miR-98 expression is altered during transition from normal into cancerous state and target PGR, PGRMC1, CYP19A1, DDX3X, and TIMP3.J Clin Endocrinol Metab. 2012 Jul;97(7):E1316-26. doi: 10.1210/jc.2012-1018. Epub 2012 Apr 6.
406	Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer.Clin Cancer Res. 2005 May 15;11(10):3949-57. doi: 10.1158/1078-0432.CCR-04-1702.
407	Exome-Wide Rare Variant Analysis From the DiscovEHR Study Identifies Novel Candidate Predisposition Genes for Endometrial Cancer.Front Oncol. 2019 Jul 5;9:574. doi: 10.3389/fonc.2019.00574. eCollection 2019.
408	Identification of a potential prognostic lncRNA-miRNA-mRNA signature in endometrial cancer based on the competing endogenous RNA network.J Cell Biochem. 2019 Nov;120(11):18845-18853. doi: 10.1002/jcb.29200. Epub 2019 Jul 24.
409	Major regulators of microRNAs biogenesis Dicer and Drosha are down-regulated in endometrial cancer.Tumour Biol. 2011 Aug;32(4):769-76. doi: 10.1007/s13277-011-0179-0. Epub 2011 May 11.
410	Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.Radiol Oncol. 2019 Sep 24;53(3):307-315. doi: 10.2478/raon-2019-0034.
411	Co-regulatory expression quantitative trait loci mapping: method and application to endometrial cancer.BMC Med Genomics. 2011 Jan 12;4:6. doi: 10.1186/1755-8794-4-6.
412	MicroRNA-424/E2F6 feedback loop modulates cell invasion, migration and EMT in endometrial carcinoma.Oncotarget. 2017 Dec 13;8(69):114281-114291. doi: 10.18632/oncotarget.23218. eCollection 2017 Dec 26.
413	Expression of receptor-binding cancer antigen expressed on SiSo cells and estrogen receptor subtypes in the normal, hyperplastic, and carcinomatous endometrium.Int J Gynecol Cancer. 2008 Jan-Feb;18(1):152-8. doi: 10.1111/j.1525-1438.2007.00966.x. Epub 2007 Apr 26.
414	Evaluation of Changes in the Expression Pattern of EDIL3 in Different Grades of Endometrial Cancer.Curr Pharm Biotechnol. 2019;20(6):483-488. doi: 10.2174/1389201020666190408112822.
415	The relationship between oncogene expression and clinical outcome in endometrial carcinoma.Curr Cancer Drug Targets. 2004 Sep;4(6):511-20. doi: 10.2174/1568009043332871.
416	The Prognostic Significance of Eukaryotic Translation Initiation Factors (eIFs) in Endometrial Cancer.Int J Mol Sci. 2019 Dec 6;20(24):6169. doi: 10.3390/ijms20246169.
417	Expression of ELF5 in endometrial carcinoma tissues and its clinical significance.Oncol Lett. 2018 Sep;16(3):3473-3480. doi: 10.3892/ol.2018.9093. Epub 2018 Jul 5.
418	Association of thymidylate synthase gene with endometrial cancer risk in a Chinese population.Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):579-84. doi: 10.1158/1055-9965.EPI-08-0831. Epub 2009 Feb 3.
419	miR-148b Functions as a Tumor Suppressor by Targeting Endoplasmic Reticulum Metallo Protease 1 in Human Endometrial Cancer Cells.Oncol Res. 2018 Dec 27;27(1):81-88. doi: 10.3727/096504018X15202988139874. Epub 2018 Mar 9.
420	Mig-6 Mouse Model of Endometrial Cancer.Adv Exp Med Biol. 2017;943:243-259. doi: 10.1007/978-3-319-43139-0_8.
421	Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targets.Oncotarget. 2012 Oct;3(10):1204-19. doi: 10.18632/oncotarget.679.
422	Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion.Clin Exp Metastasis. 2015 Jun;32(5):467-78. doi: 10.1007/s10585-015-9720-7. Epub 2015 Apr 30.
423	FAM98A promotes cancer progression in endometrial carcinoma.Mol Cell Biochem. 2019 Sep;459(1-2):131-139. doi: 10.1007/s11010-019-03556-1. Epub 2019 May 21.
424	Expression of DNA repair proteins in endometrial cancer predicts disease outcome.Gynecol Oncol. 2014 Mar;132(3):593-8. doi: 10.1016/j.ygyno.2014.02.002. Epub 2014 Feb 6.
425	FAT4-USP51 complex regulates the proliferation and invasion of endometrial cancer via Hippo pathway.Am J Transl Res. 2019 May 15;11(5):2784-2800. eCollection 2019.
426	Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair.Nat Genet. 1996 Sep;14(1):102-5. doi: 10.1038/ng0996-102.
427	The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.J Cancer Res Clin Oncol. 2004 Feb;130(2):114-21. doi: 10.1007/s00432-003-0518-7. Epub 2003 Dec 9.
428	Flotillin-1 protein is upregulated in human endometrial cancer and localization shifts from epithelial to stromal with increasing tumor grade.Cancer Invest. 2016;34(1):26-31. doi: 10.3109/07357907.2015.1084313. Epub 2015 Dec 18.
429	Generation of Mouse for Conditional Expression of Forkhead Box A2.Endocrinology. 2018 Apr 1;159(4):1897-1909. doi: 10.1210/en.2018-00158.
430	In silico, in vitro and in vivo analysis identifies a potential role for steroid hormone regulation of FOXD3 in endometriosis-associated genes.Hum Reprod. 2016 Feb;31(2):345-54. doi: 10.1093/humrep/dev307. Epub 2015 Dec 23.
431	YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.Cancer Res. 2017 Apr 1;77(7):1637-1648. doi: 10.1158/0008-5472.CAN-15-3084. Epub 2017 Feb 15.
432	GalNAc-T6 in the relationship with invasion ability of endometrial carcinomas and prognostic significance.Am J Cancer Res. 2017 May 1;7(5):1188-1197. eCollection 2017.
433	The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer.Int J Cancer. 2011 Jun 1;128(11):2613-24. doi: 10.1002/ijc.25606. Epub 2010 Oct 4.
434	Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.Oncotarget. 2017 Jan 17;8(3):4410-4421. doi: 10.18632/oncotarget.13877.
435	Clinicopathological significance of PSF3 expression in uterine endometrial carcinomas.Hum Pathol. 2018 Oct;80:104-112. doi: 10.1016/j.humpath.2018.06.010. Epub 2018 Jun 21.
436	Evaluating Myometrial Invasion in Endometrial Cancer: Comparison of Reduced Field-of-view Diffusion-weighted Imaging and Dynamic Contrast-enhanced MR Imaging.Magn Reson Med Sci. 2018 Jan 10;17(1):28-34. doi: 10.2463/mrms.mp.2016-0128. Epub 2017 May 18.
437	Golgi phosphoprotein 3 (GOLPH3) promotes endometrial carcinoma cell invasion and migration by regulating the epithelial-mesenchymal transition.Cancer Biomark. 2019;26(1):21-30. doi: 10.3233/CBM-190096.
438	Joint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk.Sci Rep. 2015 Oct 26;5:15582. doi: 10.1038/srep15582.
439	Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis.Proc Natl Acad Sci U S A. 2012 May 22;109(21):8155-60. doi: 10.1073/pnas.1117654109. Epub 2012 May 8.
440	Comprehensive Assessment of GPR68 Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody.Int J Mol Sci. 2019 Oct 23;20(21):5261. doi: 10.3390/ijms20215261.
441	Discovery of epigenetically masked tumor suppressor genes in endometrial cancer.Mol Cancer Res. 2005 May;3(5):261-9. doi: 10.1158/1541-7786.MCR-04-0110.
442	The transcriptional co-activator NCOA6 promotes estrogen-induced GREB1 transcription by recruiting ER and enhancing enhancer-promoter interactions.J Biol Chem. 2019 Dec 20;294(51):19667-19682. doi: 10.1074/jbc.RA119.010704. Epub 2019 Nov 19.
443	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.Cancer Res. 2009 Sep 1;69(17):7038-45. doi: 10.1158/0008-5472.CAN-09-1691. Epub 2009 Aug 18.
444	SUMO-1 Promotes Ishikawa Cell Proliferation and Apoptosis in Endometrial Cancer by Increasing Sumoylation of Histone H4.Int J Gynecol Cancer. 2015 Oct;25(8):1364-8. doi: 10.1097/IGC.0000000000000501.
445	Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells.BMC Med Genomics. 2019 Nov 12;12(1):163. doi: 10.1186/s12920-019-0601-9.
446	X chromosome-linked long noncoding RNA lnc-XLEC1 regulates c-Myc-dependent cell growth by collaborating with MBP-1 in endometrial cancer.Int J Cancer. 2019 Aug 15;145(4):927-940. doi: 10.1002/ijc.32166. Epub 2019 Feb 23.
447	Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma.Pathology. 2018 Aug;50(5):499-503. doi: 10.1016/j.pathol.2018.03.004. Epub 2018 Jun 8.
448	miR-10b Inhibits Apoptosis and Promotes Proliferation and Invasion of Endometrial Cancer Cells via Targeting HOXB3.Cancer Biother Radiopharm. 2016 Aug;31(6):225-31. doi: 10.1089/cbr.2016.1998.
449	HOXB9 promotes endometrial cancer progression by targeting E2F3.Cell Death Dis. 2018 May 1;9(5):509. doi: 10.1038/s41419-018-0556-3.
450	A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk.Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12263-8. doi: 10.1073/pnas.192172299. Epub 2002 Sep 6.
451	Methylation status of KLF4 and HS3ST2 genes as predictors of endometrial cancer and hyperplastic endometrial lesions.Int J Mol Med. 2018 Dec;42(6):3318-3328. doi: 10.3892/ijmm.2018.3872. Epub 2018 Sep 12.
452	Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer.Gynecol Oncol. 2005 Aug;98(2):193-202. doi: 10.1016/j.ygyno.2005.02.031.
453	RNA-seq Reveals the Overexpression of IGSF9 in Endometrial Cancer.J Oncol. 2018 Feb 14;2018:2439527. doi: 10.1155/2018/2439527. eCollection 2018.
454	Rapamycin Synergizes with Cisplatin in Antiendometrial Cancer Activation by Improving IL-27-Stimulated Cytotoxicity of NK Cells.Neoplasia. 2018 Jan;20(1):69-79. doi: 10.1016/j.neo.2017.11.003. Epub 2017 Dec 1.
455	Expression pattern and level of ING5 protein in normal and cancer tissues.Oncol Lett. 2019 Jan;17(1):63-68. doi: 10.3892/ol.2018.9581. Epub 2018 Oct 16.
456	Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin 3 via SMAD2/3 signaling.Oncotarget. 2015 Oct 13;6(31):31659-73. doi: 10.18632/oncotarget.5229.
457	Increased expression of importin13 in endometriosis and endometrial carcinoma.Med Sci Monit. 2012 Jun;18(6):CR361-7. doi: 10.12659/msm.882879.
458	Validation of endogenous control reference genes for normalizing gene expression studies in endometrial carcinoma.Mol Hum Reprod. 2015 Sep;21(9):723-35. doi: 10.1093/molehr/gav033. Epub 2015 Jun 29.
459	Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression.Oncotarget. 2016 Apr 12;7(15):20260-70. doi: 10.18632/oncotarget.7754.
460	Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women.Int J Cancer. 2009 Mar 15;124(6):1358-65. doi: 10.1002/ijc.24071.
461	Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.Cancer Med. 2020 Feb;9(3):1092-1103. doi: 10.1002/cam4.2729. Epub 2019 Dec 6.
462	AP-1 Expression and its Clinical Relevance in Immune Disorders and Cancer.Am J Med Sci. 2017 May;353(5):474-483. doi: 10.1016/j.amjms.2017.01.019. Epub 2017 Feb 1.
463	TRIB3 suppresses proliferation and invasion and promotes apoptosis of endometrial cancer cells by regulating the AKT signaling pathway.Onco Targets Ther. 2019 Mar 27;12:2235-2245. doi: 10.2147/OTT.S189001. eCollection 2019.
464	Dysregulation of Krppel-like factor 12 in the development of endometrial cancer.Gynecol Oncol. 2019 Jan;152(1):177-184. doi: 10.1016/j.ygyno.2018.10.028. Epub 2018 Oct 25.
465	Value of T cell receptor gamma alternate reading frame protein and keratin 5 in endometrial carcinoma.Chin Med J (Engl). 2013 Nov;126(22):4260-4.
466	Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.Gynecol Oncol. 2015 Nov;139(2):338-44. doi: 10.1016/j.ygyno.2015.08.025. Epub 2015 Sep 3.
467	LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma.Int J Cancer. 2016 Dec 1;139(11):2529-39. doi: 10.1002/ijc.30371. Epub 2016 Aug 16.
468	miR?15 promotes epithelial to mesenchymal transition and proliferation by regulating LEFTY2 in endometrial cancer.Int J Mol Med. 2018 Sep;42(3):1229-1236. doi: 10.3892/ijmm.2018.3703. Epub 2018 May 22.
469	Galectin-7 is elevated in endometrioid (type I) endometrial cancer and promotes cell migration.Oncol Lett. 2018 Oct;16(4):4721-4728. doi: 10.3892/ol.2018.9193. Epub 2018 Jul 23.
470	Loss of Hugl-1 expression associates with lymph node metastasis in endometrial cancer.Oncol Res. 2007;16(9):431-5. doi: 10.3727/000000007783980855.
471	LRG1 is an independent prognostic factor for endometrial carcinoma.Tumour Biol. 2014 Jul;35(7):7125-33. doi: 10.1007/s13277-014-1953-6. Epub 2014 Apr 24.
472	LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data.BMC Cancer. 2018 May 2;18(1):494. doi: 10.1186/s12885-018-4429-z.
473	Correlation of MACC1/c-Myc Expression in Endometrial Carcinoma with Clinical/Pathological Features or Prognosis.Med Sci Monit. 2018 Jul 9;24:4738-4744. doi: 10.12659/MSM.908812.
474	Induction of the LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through the downregulation of E-cadherin.Cell Res. 2007 Oct;17(10):869-80. doi: 10.1038/cr.2007.79.
475	The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.J Gynecol Oncol. 2018 Jan;29(1):e17. doi: 10.3802/jgo.2018.29.e17.
476	CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer.J Clin Pathol. 2014 Dec;67(12):1067-71. doi: 10.1136/jclinpath-2014-202616. Epub 2014 Oct 3.
477	SOX17 is a tumor suppressor in endometrial cancer.Oncotarget. 2016 Nov 15;7(46):76036-76046. doi: 10.18632/oncotarget.12582.
478	Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer.Oncology. 2010;79(3-4):238-46. doi: 10.1159/000322644. Epub 2011 Mar 3.
479	Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial.JAMA. 2017 Mar 28;317(12):1224-1233. doi: 10.1001/jama.2017.2068.
480	miR-27b-3p/MARCH7 regulates invasion and metastasis of endometrial cancer cells through Snail-mediated pathway.Acta Biochim Biophys Sin (Shanghai). 2019 May 23;51(5):492-500. doi: 10.1093/abbs/gmz030.
481	Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer.Am J Epidemiol. 2013 Jun 15;177(12):1317-25. doi: 10.1093/aje/kws394. Epub 2013 May 31.
482	Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.Anticancer Res. 2001 Jul-Aug;21(4B):2925-32.
483	MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization.J Natl Cancer Inst. 2018 May 1;110(5):517-526. doi: 10.1093/jnci/djx238.
484	MDH2 Stimulated by Estrogen-GPR30 Pathway Down-Regulated PTEN Expression Promoting the Proliferation and Invasion of Cells in Endometrial Cancer.Transl Oncol. 2017 Apr;10(2):203-210. doi: 10.1016/j.tranon.2017.01.009. Epub 2017 Feb 9.
485	Expression of the zinc finger gene EVI-1 in ovarian and other cancers.Br J Cancer. 1996 Nov;74(10):1518-25. doi: 10.1038/bjc.1996.583.
486	m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.Nat Cell Biol. 2018 Sep;20(9):1074-1083. doi: 10.1038/s41556-018-0174-4. Epub 2018 Aug 27.
487	Aquaporin-1 plays a crucial role in estrogen-induced tubulogenesis of vascular endothelial cells.J Clin Endocrinol Metab. 2013 Apr;98(4):E672-82. doi: 10.1210/jc.2012-4081. Epub 2013 Feb 28.
488	MLH3 mutation in endometrial cancer.Cancer Res. 2006 Aug 1;66(15):7502-8. doi: 10.1158/0008-5472.CAN-06-0248.
489	Estrogen and estrogen receptor induce matrix metalloproteinase-26 expression in endometrial carcinoma cells.Oncol Rep. 2013 Aug;30(2):751-6. doi: 10.3892/or.2013.2527. Epub 2013 Jun 7.
490	The MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4-dependent migration of cancer cells.Sci Rep. 2018 Feb 2;8(1):2268. doi: 10.1038/s41598-018-20765-8.
491	A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry.Am J Obstet Gynecol. 1989 Oct;161(4):1079-86. doi: 10.1016/0002-9378(89)90787-4.
492	Epigenetic alteration of the metallothionein 1E gene in human endometrial carcinomas.Tumour Biol. 2009;30(2):93-9. doi: 10.1159/000218032. Epub 2009 May 6.
493	Immunohistochemical expression of HIK1083 and MUC6 in endometrial carcinomas.Histopathology. 2019 Oct;75(4):552-558. doi: 10.1111/his.13887. Epub 2019 Aug 8.
494	DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer.Oncotarget. 2016 Dec 20;7(51):84785-84797. doi: 10.18632/oncotarget.12626.
495	Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas.Int J Gynecol Cancer. 2018 Sep;28(7):1318-1324. doi: 10.1097/IGC.0000000000001303.
496	Steroid Receptor Coactivator-2 Controls the Pentose Phosphate Pathway through RPIA in Human Endometrial Cancer Cells.Sci Rep. 2018 Sep 3;8(1):13134. doi: 10.1038/s41598-018-31372-y.
497	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8(+) T-cell Function.Cancer Immunol Res. 2019 Feb;7(2):257-268. doi: 10.1158/2326-6066.CIR-18-0442. Epub 2019 Jan 18.
498	Neural precursor cell-expressed developmentally down-regulated 4-like: a new biomarker in the pathophysiology of endometrial cancer.J Int Med Res. 2018 Sep;46(9):3709-3716. doi: 10.1177/0300060518777944. Epub 2018 Jul 12.
499	Prognostic role of NF-YA splicing isoforms and Lamin A status in low grade endometrial cancer.Oncotarget. 2017 Jan 31;8(5):7935-7945. doi: 10.18632/oncotarget.13854.
500	Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma.J BUON. 2016 Nov-Dec;21(6):1491-1495.
501	Inflammasome as a Key Pathogenic Mechanism in Endometriosis.Curr Drug Targets. 2017;18(9):997-1002. doi: 10.2174/1389450117666160709013850.
502	Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.Cancer Lett. 2018 Jan 28;413:23-34. doi: 10.1016/j.canlet.2017.10.028. Epub 2017 Oct 26.
503	Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p.Aging (Albany NY). 2019 Dec 4;11(23):11609-11623. doi: 10.18632/aging.102563. Epub 2019 Dec 4.
504	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.Nat Genet. 2016 Aug;48(8):848-55. doi: 10.1038/ng.3602. Epub 2016 Jun 27.
505	miR-34a, miR-424 and miR-513 inhibit MMSET expression to repress endometrial cancer cell invasion and sphere formation.Oncotarget. 2018 May 1;9(33):23253-23263. doi: 10.18632/oncotarget.25298. eCollection 2018 May 1.
506	Select human cancer mutants of NRMT1 alter its catalytic activity and decrease N-terminal trimethylation.Protein Sci. 2017 Aug;26(8):1639-1652. doi: 10.1002/pro.3202. Epub 2017 Jun 11.
507	Differential expression of NUDT9 at different phases of the menstrual cycle and in different components of normal and neoplastic human endometrium.Taiwan J Obstet Gynecol. 2009 Jun;48(2):96-107. doi: 10.1016/S1028-4559(09)60266-7.
508	OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity.J Biol Chem. 2009 Jun 12;284(24):16135-16145. doi: 10.1074/jbc.M109.007484. Epub 2009 Apr 21.
509	The Roles of Glycodelin in Cancer Development and Progression.Front Immunol. 2017 Nov 29;8:1685. doi: 10.3389/fimmu.2017.01685. eCollection 2017.
510	Membrane progesterone receptors and have potential as prognostic biomarkers of endometrial cancer.J Steroid Biochem Mol Biol. 2018 Apr;178:303-311. doi: 10.1016/j.jsbmb.2018.01.011. Epub 2018 Jan 17.
511	The promising role of PAX1 (aliases: HUP48, OFC2) gene methylation in cancer screening.Mol Genet Genomic Med. 2019 Mar;7(3):e506. doi: 10.1002/mgg3.506. Epub 2019 Jan 12.
512	PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: A systematic review and meta-analysis of diagnostic accuracy.Acta Obstet Gynecol Scand. 2019 Mar;98(3):287-299. doi: 10.1111/aogs.13512. Epub 2019 Jan 8.
513	Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.Virchows Arch. 2019 Jul;475(1):85-94. doi: 10.1007/s00428-019-02532-w. Epub 2019 Feb 9.
514	Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression.Cancer. 2003 Nov 15;98(10):2207-13. doi: 10.1002/cncr.11760.
515	A novel wnt regulatory axis in endometrioid endometrial cancer.Cancer Res. 2014 Sep 15;74(18):5103-17. doi: 10.1158/0008-5472.CAN-14-0427. Epub 2014 Aug 1.
516	Endoplasmic reticulum stress-mediated membrane expression of CRT/ERp57 induces immunogenic apoptosis in drug-resistant endometrial cancer cells.Oncotarget. 2017 May 8;8(35):58754-58764. doi: 10.18632/oncotarget.17678. eCollection 2017 Aug 29.
517	PELP1 is a novel oncogene in gastric tumorigenesis and negatively regulated by miR-15 family microRNAs.Cancer Biomark. 2019;26(1):1-9. doi: 10.3233/CBM-182279.
518	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.Clin Cancer Res. 2018 Jul 15;24(14):3253-3262. doi: 10.1158/1078-0432.CCR-17-3421. Epub 2018 Apr 10.
519	Piwil1 causes epigenetic alteration of PTEN gene via upregulation of DNA methyltransferase in type I endometrial cancer.Biochem Biophys Res Commun. 2015 Aug 7;463(4):876-80. doi: 10.1016/j.bbrc.2015.06.028. Epub 2015 Jun 6.
520	Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway.Hum Mol Genet. 2006 Jan 15;15(2):201-11. doi: 10.1093/hmg/ddi430. Epub 2005 Dec 23.
521	AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.Gynecol Oncol. 2010 Jan;116(1):88-91. doi: 10.1016/j.ygyno.2009.09.038. Epub 2009 Oct 22.
522	Progesterone and 1,25-dihydroxyvitamin D? inhibit endometrial cancer cell growth by upregulating semaphorin 3B and semaphorin 3F. Mol Cancer Res. 2011 Nov;9(11):1479-92. doi: 10.1158/1541-7786.MCR-11-0213. Epub 2011 Sep 20.
523	Granular dot-like staining with MLH1 immunohistochemistry is a clone-dependent artefact.Pathol Res Pract. 2020 Jan;216(1):152581. doi: 10.1016/j.prp.2019.152581. Epub 2019 Aug 5.
524	The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients.J Gynecol Oncol. 2018 Sep;29(5):e72. doi: 10.3802/jgo.2018.29.e72. Epub 2018 May 4.
525	Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.Gynecol Oncol. 2016 Apr;141(1):113-20. doi: 10.1016/j.ygyno.2015.12.031. Epub 2015 Dec 31.
526	Expression of hPOT1 in HeLa cells and the probability of gene variation of hpot1 Exon14 in endometrial cancer are much higher than in other cancers.Asian Pac J Cancer Prev. 2012;13(11):5659-63. doi: 10.7314/apjcp.2012.13.11.5659.
527	Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.Cancer Res. 2019 Aug 15;79(16):4009-4010. doi: 10.1158/0008-5472.CAN-19-1938.
528	Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.J Surg Oncol. 2011 Dec;104(7):755-9. doi: 10.1002/jso.22035. Epub 2011 Jul 14.
529	Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.Oncology. 2005;69(4):317-25. doi: 10.1159/000089764. Epub 2005 Nov 17.
530	Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer.J Clin Oncol. 1998 Mar;16(3):1085-93. doi: 10.1200/JCO.1998.16.3.1085.
531	Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.Gene. 2019 Jun 20;702:66-74. doi: 10.1016/j.gene.2019.03.063. Epub 2019 Mar 28.
532	Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REG.Cancer Lett. 2015 May 1;360(2):269-79. doi: 10.1016/j.canlet.2015.02.028. Epub 2015 Feb 16.
533	Downregulation of PTPN18 can inhibit proliferation and metastasis and promote apoptosis of endometrial cancer.Clin Exp Pharmacol Physiol. 2019 Aug;46(8):734-742. doi: 10.1111/1440-1681.13098. Epub 2019 May 30.
534	Differential expression of the alpha(2)-macroglobulin receptor and the receptor associated protein in normal human endometrium and endometrial carcinoma.Mol Hum Reprod. 2000 Oct;6(10):921-7. doi: 10.1093/molehr/6.10.921.
535	Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis.Gynecol Oncol. 2017 Sep;146(3):603-608. doi: 10.1016/j.ygyno.2017.06.017. Epub 2017 Jun 29.
536	Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis.Horm Cancer. 2011 Jun;2(3):170-81. doi: 10.1007/s12672-011-0065-7.
537	Expression of Rb2/p130 in breast and endometrial cancer: correlations with hormone receptor status.Br J Cancer. 2001 Aug 17;85(4):546-51. doi: 10.1054/bjoc.2001.1923.
538	Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation.Mod Pathol. 2019 May;32(5):650-658. doi: 10.1038/s41379-018-0179-3. Epub 2018 Nov 15.
539	Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma.J Pathol. 2004 Dec;204(5):569-77. doi: 10.1002/path.1666.
540	MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC).Oncotarget. 2016 Feb 9;7(6):6649-64. doi: 10.18632/oncotarget.6544.
541	Elevated expression of RIT1 correlates with poor prognosis in endometrial cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10315-24. eCollection 2015.
542	Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer.Oncotarget. 2016 Aug 23;7(34):55249-55263. doi: 10.18632/oncotarget.10509.
543	Pir2/Rnf144b is a potential endometrial cancer biomarker that promotes cell proliferation. Cell Death Dis. 2018 May 1;9(5):504. doi: 10.1038/s41419-018-0521-1.
544	Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.JAMA Oncol. 2015 Dec;1(9):1319-23. doi: 10.1001/jamaoncol.2015.2151.
545	Frequent mutations in the RPL22 gene and its clinical and functional implications.Gynecol Oncol. 2013 Mar;128(3):470-4. doi: 10.1016/j.ygyno.2012.10.026. Epub 2012 Nov 2.
546	RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma.Diagn Pathol. 2019 Jan 26;14(1):7. doi: 10.1186/s13000-019-0784-6.
547	High expression of SALL4 and fascin, and loss of E-cadherin expression in undifferentiated/dedifferentiated carcinomas of the endometrium: An immunohistochemical and clinicopathologic study.Medicine (Baltimore). 2017 Mar;96(10):e6248. doi: 10.1097/MD.0000000000006248.
548	The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts.Cell Cycle. 2010 Nov 1;9(21):4387-98. doi: 10.4161/cc.9.21.13674. Epub 2010 Nov 17.
549	Expression of Semaphorin 3B (SEMA3B) in Various Grades of Endometrial Cancer.Med Sci Monit. 2019 Jun 20;25:4569-4574. doi: 10.12659/MSM.916762.
550	Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer.Curr Pharm Biotechnol. 2020;21(1):45-51. doi: 10.2174/1389201020666190911113611.
551	Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells.Br J Cancer. 2004 Nov 15;91(10):1808-12. doi: 10.1038/sj.bjc.6602214.
552	Interactions between microRNA-200 family and Sestrin proteins in endometrial cancer cell lines and their significance to anoikis.Mol Cell Biochem. 2019 Sep;459(1-2):21-34. doi: 10.1007/s11010-019-03547-2. Epub 2019 May 9.
553	Association of body mass index with ER, PR and 14-3-3 expression in tumor and stroma of type I and type II endometrial carcinoma.Oncotarget. 2017 Jun 27;8(26):42548-42559. doi: 10.18632/oncotarget.17209.
554	CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility.Cancer. 2008 May 1;112(9):1964-73. doi: 10.1002/cncr.23392.
555	Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.Endocrinology. 2013 Nov;154(11):4030-45. doi: 10.1210/en.2013-1757. Epub 2013 Sep 13.
556	Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells.J Nutr Biochem. 2017 Jun;44:60-70. doi: 10.1016/j.jnutbio.2016.12.021. Epub 2017 Mar 16.
557	MicroRNA?09 may function as a tumor suppressor in endometrial carcinoma cells by targeting Smad2.Mol Med Rep. 2019 Jan;19(1):622-628. doi: 10.3892/mmr.2018.9642. Epub 2018 Nov 12.
558	Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.Histopathology. 2017 Feb;70(3):359-366. doi: 10.1111/his.13091. Epub 2016 Nov 16.
559	Expression of BAF57 in ovarian cancer cells and drug sensitivity.Cancer Sci. 2015 Apr;106(4):359-66. doi: 10.1111/cas.12612. Epub 2015 Feb 25.
560	Long noncoding RNA TUSC7 inhibits cell proliferation, migration and invasion by regulating SOCS4 (SOCS5) expression through targeting miR-616 in endometrial carcinoma.Life Sci. 2019 Aug 15;231:116549. doi: 10.1016/j.lfs.2019.116549. Epub 2019 Jun 12.
561	DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia.Gynecol Oncol. 2014 Dec;135(3):552-9. doi: 10.1016/j.ygyno.2014.10.018. Epub 2014 Oct 23.
562	SOX17, -catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression.Cancer Gene Ther. 2020 Apr;27(3-4):256-263. doi: 10.1038/s41417-019-0135-5. Epub 2019 Sep 23.
563	SOX11 hypermethylation as a tumor biomarker in endometrial cancer.Biochimie. 2019 Jul;162:8-14. doi: 10.1016/j.biochi.2019.03.019. Epub 2019 Mar 29.
564	Overexpression of microRNA-194 suppresses the epithelial-mesenchymal transition in targeting stem cell transcription factor Sox3 in endometrial carcinoma stem cells.Tumour Biol. 2017 Jun;39(6):1010428317706217. doi: 10.1177/1010428317706217.
565	UBE2S mediates tumor progression via SOX6/-Catenin signaling in endometrial cancer.Int J Biochem Cell Biol. 2019 Apr;109:17-22. doi: 10.1016/j.biocel.2019.01.014. Epub 2019 Jan 25.
566	F-Spondin Is the Signal by Which 2-Methoxyestradiol Induces Apoptosis in the Endometrial Cancer Cell Line Ishikawa.Int J Mol Sci. 2019 Aug 7;20(16):3850. doi: 10.3390/ijms20163850.
567	The ubiquitin ligase adaptor SPOP in cancer.FEBS J. 2019 Oct;286(20):3946-3958. doi: 10.1111/febs.15056. Epub 2019 Sep 18.
568	Association between the expression of secreted phosphoprotein - related genes and prognosis of human cancer.BMC Cancer. 2019 Dec 18;19(1):1230. doi: 10.1186/s12885-019-6441-3.
569	Associations between a single nucleotide polymorphism of stress-induced phosphoprotein 1 and endometriosis/adenomyosis.Taiwan J Obstet Gynecol. 2018 Apr;57(2):270-275. doi: 10.1016/j.tjog.2018.03.001.
570	Nomegestrol Acetate Suppresses Human Endometrial Cancer RL95-2 Cells Proliferation In Vitro and In Vivo Possibly Related to Upregulating Expression of SUFU and Wnt7a.Int J Mol Sci. 2017 Jun 22;18(7):1337. doi: 10.3390/ijms18071337.
571	Downregulation of endometrial mesenchymal marker SUSD2 causes cell senescence and cell death in endometrial carcinoma cells.PLoS One. 2017 Aug 25;12(8):e0183681. doi: 10.1371/journal.pone.0183681. eCollection 2017.
572	MicroRNA-182 promotes tumor cell growth by targeting transcription elongation factor A-like 7 in endometrial carcinoma.Cell Physiol Biochem. 2013;32(3):581-90. doi: 10.1159/000354462. Epub 2013 Sep 6.
573	ZEB1 promotes invasion and metastasis of endometrial cancer by interacting with HDGF and inducing its transcription.Am J Cancer Res. 2019 Nov 1;9(11):2314-2330. eCollection 2019.
574	Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer.Hum Pathol. 2013 Jan;44(1):103-9. doi: 10.1016/j.humpath.2012.04.021. Epub 2012 Aug 30.
575	Tead and AP1 Coordinate Transcription and Motility.Cell Rep. 2016 Feb 9;14(5):1169-1180. doi: 10.1016/j.celrep.2015.12.104. Epub 2016 Jan 28.
576	TESTIN was commonly hypermethylated and involved in the epithelial-mesenchymal transition of endometrial cancer.APMIS. 2015 May;123(5):394-400. doi: 10.1111/apm.12361. Epub 2015 Feb 27.
577	Differential expression of ten-eleven translocation genes in endometrial cancers.Tumour Biol. 2017 Mar;39(3):1010428317695017. doi: 10.1177/1010428317695017.
578	Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.Gynecol Oncol. 2018 Jun;149(3):592-597. doi: 10.1016/j.ygyno.2018.03.057. Epub 2018 Mar 28.
579	Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells.Oncotarget. 2017 Aug 24;8(44):77268-77291. doi: 10.18632/oncotarget.20461. eCollection 2017 Sep 29.
580	Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis.Int J Oncol. 2001 Aug;19(2):305-10. doi: 10.3892/ijo.19.2.305.
581	Imbalanced expression of TAN-1 and human Notch4 in endometrial cancers.Int J Oncol. 2000 Dec;17(6):1131-9. doi: 10.3892/ijo.17.6.1131.
582	Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.Cancer Res. 2016 Oct 1;76(19):5719-5731. doi: 10.1158/0008-5472.CAN-15-3342. Epub 2016 Aug 2.
583	TMEFF2 is a novel prognosis signature and target for endometrial carcinoma.Life Sci. 2020 Feb 15;243:116910. doi: 10.1016/j.lfs.2019.116910. Epub 2019 Oct 11.
584	Association of TNFAIP8 gene polymorphisms with endometrial cancer in northern Chinese women.Cancer Cell Int. 2019 Apr 23;19:105. doi: 10.1186/s12935-019-0827-9. eCollection 2019.
585	Identification of DNA methylation associated gene signatures in endometrial cancer via integrated analysis of DNA methylation and gene expression systematically.J Gynecol Oncol. 2017 Nov;28(6):e83. doi: 10.3802/jgo.2017.28.e83.
586	Targeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activity.Mol Cancer Ther. 2009 Aug;8(8):2412-23. doi: 10.1158/1535-7163.MCT-09-0186. Epub 2009 Aug 11.
587	Expression of TRA2B in endometrial carcinoma and its regulatory roles in endometrial carcinoma cells.Oncol Lett. 2019 Sep;18(3):2455-2463. doi: 10.3892/ol.2019.10553. Epub 2019 Jul 3.
588	RETRACTED: TRAF4 promotes endometrial cancer cell growth and migration by activation of PI3K/AKT/Oct4 signaling.Exp Mol Pathol. 2019 Jun;108:9-16. doi: 10.1016/j.yexmp.2019.03.003. Epub 2019 Mar 7.
589	Effects of Intermediate-Conductance Ca(2+)-Activated K(+) Channels on Human Endometrial Carcinoma Cells.Cell Biochem Biophys. 2015 Jun;72(2):515-25. doi: 10.1007/s12013-014-0497-0.
590	Identification of TRIM22 as a progesterone-responsive gene in Ishikawa endometrial cancer cells.J Steroid Biochem Mol Biol. 2015 Nov;154:217-25. doi: 10.1016/j.jsbmb.2015.08.024. Epub 2015 Aug 24.
591	High TRIM44 expression in endometrial carcinoma is associated with a poorer patient outcome.Pathol Res Pract. 2018 May;214(5):727-731. doi: 10.1016/j.prp.2018.03.007. Epub 2018 Mar 6.
592	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.Sci Rep. 2015 Dec 1;5:17369. doi: 10.1038/srep17369.
593	Expression of tumor suppressor genes related to the cell cycle in endometrial cancer patients.Adv Med Sci. 2016 Sep;61(2):317-324. doi: 10.1016/j.advms.2016.04.001. Epub 2016 Apr 13.
594	LVSI positive and NX in early endometrial cancer: Surgical restaging (and no further treatment if N0), or adjuvant ERT?.Gynecol Oncol. 2020 Jan;156(1):243-250. doi: 10.1016/j.ygyno.2019.09.016. Epub 2019 Nov 5.
595	Expression of the Receptor for Hyaluronic Acid-Mediated Motility (RHAMM) in Endometrial Cancer is Associated With Adverse Histologic Parameters and Tumor Progression.Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):453-459. doi: 10.1097/PAI.0000000000000763.
596	Hypoxia is involved in the reduction of HtrA3 in patients with endometrial hyperplasia and cancer.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2918-2923. doi: 10.1016/j.bbrc.2018.08.070. Epub 2018 Aug 20.
597	Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy.Oncology. 2019;96(5):235-241. doi: 10.1159/000492430. Epub 2019 Mar 22.
598	High expression of MUC20 drives tumorigenesis and predicts poor survival in endometrial cancer.J Cell Biochem. 2019 Jul;120(7):11859-11866. doi: 10.1002/jcb.28466. Epub 2019 Feb 19.
599	Abnormal Expression of PICT-1 and Its Codon 389 Polymorphism Is a Risk Factor for Human Endometrial Cancer.Oncology. 2018;95(1):43-51. doi: 10.1159/000487189. Epub 2018 Apr 4.
600	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.Gynecol Oncol. 2020 Jan;156(1):194-202. doi: 10.1016/j.ygyno.2019.10.028. Epub 2019 Nov 19.
601	Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.Mod Pathol. 2006 Jun;19(6):797-803. doi: 10.1038/modpathol.3800586.
602	Investigation of resistin 420 and 62 gene polymorphism in patients with endometrial cancer.Taiwan J Obstet Gynecol. 2019 Jan;58(1):164-167. doi: 10.1016/j.tjog.2018.11.030.